Page last updated: 2024-11-04

meperidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4058
CHEMBL ID607
CHEBI ID6754
SCHEMBL ID25431
MeSH IDM0013427

Synonyms (93)

Synonym
DIVK1C_000983
KBIO1_000983
einecs 200-329-1
1-methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [german]
nemerol
petidina [inn-spanish]
isonipecain
pethidinum [inn-latin]
n-methyl-4-phenyl-4-carbethoxypiperidine
petydyna [polish]
dea no. 9230
IDI1_000983
pipersal
1-methyl-4-phenylisonipecotic acid, ethyl ester
hsdb 3116
methyl phenylpiperidine carbonic acid ethyl ester
ethyl 1-methyl-4-phenylisonipecotate
pethanol
meperidol
ethyl 1-methyl-4-phenylpiperidine-4-carboxylate
1-methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester
4-carbethoxy-1-methyl-4-phenylpiperidine
isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester
pethidineter
pethidin
phetidine
demerol
isonipecaine
4-piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester
yisonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8ci)
1-methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester
pethidine
57-42-1
C07128
meperidine
DB00454
NINDS_000983
L000908
CHEMBL607 ,
pethidine dbl
chebi:6754 ,
ids-np-001
renaudin
pethidine (inn)
D08343
pethidine dbl (tn)
4-ethoxycarbonyl-1-methyl-4-phenyl-piperidinium
1-methyl-4-phenyl-piperidine-4-carboxylic acid ethyl ester
bdbm50026752
1-methyl-4-phenyl-piperidine-4-carboxylic acid ethyl ester(meperidine)
demarol
piperosal
9e338qe28f ,
unii-9e338qe28f
petydyna
1-methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester
petidina
pethidinum
pethidine [inn:ban]
pethidine [inn]
meperidine [vandf]
meperidine [hsdb]
pethidine [who-dd]
meperidine [mi]
gtpl7221
SCHEMBL25431
meperidina
1-methyl-4-phenylisonipecotic acid ethyl ester
centralgin (salt/mix)
dolcontral (salt/mix)
operidine (salt/mix)
dolsin (salt/mix)
petantin (salt/mix)
dolosal (salt/mix)
dolantin (salt/mix)
lydol (salt/mix)
ethyl 1-methyl-4-phenyl-4-piperidinecarboxylate
piridosal (salt/mix)
dispadol (salt/mix)
dolaren (salt/mix)
lidol (salt/mix)
mepridine
DTXSID9023253 ,
sr-01000944492
SR-01000944492-1
pethidine (meperidine) 1.0 mg/ml in methanol
pethidine (meperidine) 0.1 mg/ml in methanol
Q55434
pethidinum (latin)
dtxcid403253
pethidinum (inn-latin)
petidina (inn-spanish)
n02ab02

Research Excerpts

Overview

Meperidine (pethidine) is a µ-opioid receptor (MOR) agonist widely used in the treatment of cancer pain. Meperidine is a potent agonist at the alpha2 adrenoceptors at its clinically relevant concentrations.

ExcerptReferenceRelevance
"Meperidine (pethidine) is a µ-opioid receptor (MOR) agonist widely used in the treatment of cancer pain. "( A hypothetical proposal to employ meperidine and tamoxifen in treatment of glioblastoma. Role of P-glycoprotein, ceramide and metabolic pathways.
Altinoz, MA; Hacker, E; Ozpinar, A, 2022
)
2.44
"Meperidine is a synthetic opioid that belongs to the phenylpiperidine class and is a weak mu receptor agonist. "( Meperidine pharmacokinetics and effects on physiologic parameters and thermal threshold following intravenous administration of three doses to horses.
Hamamoto-Hardman, BD; Kass, PH; Knych, HK; McKemie, DS; Steffey, EP, 2020
)
3.44
"Meperidine (Demerol(®)) is a mu- and kappa-opiate receptor agonist used for moderate to severe pain. "( Factors impacting variability of the urinary normeperidine-to-meperidine metabolic ratio in patients with chronic pain.
Atayee, RS; Best, BM; Ma, JD; Moy, KV,
)
1.83
"Meperidine (pethidine) is an opioid analgesic that offers little advantage relative to other opioids and several disadvantages including limited potency, short duration of action, and the production of a neurotoxic metabolite (normeperidine) with a long half-life. "( The safety of meperidine prescribing in older adults: A longitudinal population-based study.
Bugden, S; Falk, J; Friesen, KJ, 2016
)
2.24
"Meperidine (Demerol) is a synthetic opiate that has been utilized for decades. "( An estimate of meperidine usage in West Virginia hospitals.
Lafferty, HW; Terpening, CM,
)
1.93
"Meperidine is an opiod analgesic used in a variety of clinical situations. "( [Convulsion due to application of low dose meperidine: a case report].
Akbaş, M; Akcan, AB; Aydemir, G; Ozkaya, H, 2012
)
2.08
"Meperidine is a potent agonist at the alpha2 adrenoceptors at its clinically relevant concentrations, especially at the alpha(2B)-adrenoceptor subtype. "( Meperidine exerts agonist activity at the alpha(2B)-adrenoceptor subtype.
Bertaccini, E; Clark, DJ; Davies, MF; Krause, TK; Maze, M; Takada, K; Tonner, PH, 2002
)
3.2
"Meperidine is an opioid analgesic metabolized in the liver by N-demethylation to normeperidine, a potent stimulant of the central nervous system. "( CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Flockhart, DA; Innocenti, F; Ramírez, J; Ratain, MJ; Relling, MV; Santucci, R; Schuetz, EG, 2004
)
1.99
"Meperidine is a commonly used analgesic despite unique disadvantages compared with other opioid analgesics. "( Eliminating analgesic meperidine use with a supported formulary restriction.
Lang, VJ; O'Connor, AB; Quill, TE, 2005
)
2.09
"Meperidine is an opioid with local anesthetic properties that produces spinal anesthesia after subarachnoid injection for surgical procedures. "( Spinal anesthesia with meperidine as the sole agent for cesarean delivery.
Bonnet, F; Ngû, TH; Nguyen Thi, TV; Orliaguet, G,
)
1.88
"Meperidine is a mu opiate agonist that is frequently used to treat pain. "( Subjective, behavioral and physiological responses to intravenous meperidine in healthy volunteers.
Binstock, W; Coalson, DW; Cutter, T; Flemming, DC; Glosten, B; Lichtor, JL; Zacny, JP, 1993
)
1.97
"Meperidine is a synthetic opioid analgesic frequently prescribed in the emergency department. "( Meperidine: therapeutic use and toxicity.
Anderson, PO; Clark, RF; Wei, EM,
)
3.02
"Meperidine is a widely prescribed opioid analgesic used in a variety of clinical situations. "( Meperidine-induced generalized seizures with normal renal function.
Marinella, MA, 1997
)
3.18
"Meperidine is a potent narcotic related chemically and pharmacologically to morphine and atropine. "( Potent reduction of basal acid output produced by meperidine.
Fernandez, GG; Gaon, D; Meeroff, JC, 1978
)
1.95
"Meperidine is an opioid agonist with known weak local anesthetic properties. "( Efficacy of subarachnoid meperidine for labor analgesia.
Sholte, FG; Skerman, JH; Swayze, CR; Walker, EB,
)
1.88
"Meperidine is an effective method of reducing the elevated metabolic demand of shivering."( Effect of meperidine on oxygen consumption, carbon dioxide production, and respiratory gas exchange in postanesthesia shivering.
Dwersteg, JF; Macintyre, PE; Pavlin, EG, 1987
)
1.4

Effects

Meperidine (Demerol) has local anesthetic properties separate from its opioid receptor agonist effect. Meperidine has been associated with seizure activity when administered via traditional routes.

ExcerptReferenceRelevance
"Meperidine has been shown to exhibit a sensory block in peripheral nerves. "( Perineural meperidine blocks nerve conduction in a dose-related manner: a randomized double-blind study.
Beyazova, M; Kaya, K; Meray, J; Oztürk, E; Tarhan, B; Zinnuroglu, M, 2009
)
2.19
"Meperidine has local anaesthetic properties in addition to its opiate properties."( Spinal anaesthesia for outpatient surgery.
Urmey, WF, 2003
)
1.04
"Meperidine has potent antishivering properties. "( The effect of meperidine on thermoregulation in mice: involvement of alpha2-adrenoceptors.
Bein, B; Marquardt, M; Ohlendorf, C; Paris, A; Scholz, J; Sonner, JM; Tonner, PH, 2005
)
2.13
"Meperidine (Demerol) has local anesthetic properties separate from its opioid receptor agonist effect. "( Spinal anesthesia with meperidine: will epinephrine prolong its duration?
Benke, G; Bostrom, MA; Cohen, S; Melnyk, DL; Pakiz, AM, 1994
)
2.04
"Meperidine has been associated with seizure activity when administered via traditional routes."( Meperidine-related seizures associated with patient-controlled analgesia pumps.
Hagmeyer, KO; Mauro, LS; Mauro, VF, 1993
)
2.45
"Meperidine has atypical opioid receptor agonist effects and shares some structural features with the phenyltropane (WIN) analogs of cocaine. "( The cocaine-like behavioral effects of meperidine are mediated by activity at the dopamine transporter.
Cox, BM; Izenwasser, S; Katz, JL; Newman, AH, 1996
)
2.01
"Meperidine has local anesthetic properties and, therefore, when given epidurally it has the potential to cause hemodynamic changes. "( Epidural meperidine does not cause hemodynamic changes in the term parturient.
Critchley, LA; Khaw, KS; Ngan Kee, WD, 2000
)
2.17
"Meperidine has been used to suppress postanesthesia shivering. "( Effect of meperidine on oxygen consumption, carbon dioxide production, and respiratory gas exchange in postanesthesia shivering.
Dwersteg, JF; Macintyre, PE; Pavlin, EG, 1987
)
2.12

Actions

Meperidine did not increase the intensity at which monkeys maintained the shock in the shock titration procedure. Meperidine could suppress visible shivering and reduce postoperative VO2 to the levels seen after TIVA.

ExcerptReferenceRelevance
"Meperidine did not increase the intensity at which monkeys maintained the shock in the shock titration procedure, nor did meperidine alter the percentage of correct responses under the shock intensity discrimination although meperidine did increase the time to respond in the presence and absence of shock."( Meperidine's effect under shock titration and shock discrimination procedures.
Dykstra, LA, 1980
)
2.43
"Meperidine could suppress visible shivering and reduce postoperative VO2 to the levels seen after TIVA."( [O2 uptake in the recovery period. The effect of the anesthetic procedure and the postoperative administration of pethidine].
Hausmann, D; Krajewski, W; Nadstawek, J, 1991
)
1
"Meperidine did not produce responding on the red keys, nor did diazepam, cocaine, d-amphetamine, phencyclidine or pentobarbital."( Morphine discrimination in the pigeon using a color tracking procedure.
Paule, MG; Wenger, GR, 1986
)
0.99

Treatment

Treatment with meperidine hydrochloride, currently the most widely used medication for controlling amphotericin B-induced shivering, was compared with nefopam hydrochlorides. Meperidine treatment causes ECG changes (QTc-interval prolongation) in high correlation with normeperidine plasma concentration.

ExcerptReferenceRelevance
"Meperidine treatment causes ECG changes (QTc-interval prolongation) in high correlation with normeperidine plasma concentration. "( Meperidine-induced QTc-interval prolongation: prevalence, risk factors, and correlation to plasma drug and metabolite concentrations
.
Di Girolamo, G; Diez, RA; Fernández, N; Keller, GA; Olivera, NM; Quiroga, PN; Villa Etchegoyen, MC, 2017
)
3.34
"Treatment with meperidine hydrochloride, currently the most widely used medication for controlling amphotericin B-induced shivering, was compared with nefopam hydrochloride, which has been successfully used to treat post-operative shivering."( Efficacy of nefopam for the prevention and treatment of amphotericin B-induced shivering.
Cogliati, A; Conti, G; Dell'Utri, D; Gasparetto, A; Orsi, P; Pelaia, P; Rosa, G, 1997
)
0.64
"Treatment with meperidine resulted in phasic contractions with minimum and maximum pressures of 27.9 +/- 4.55 and 98.9 +/- 9.16 mm of Hg, respectively."( Effects of atropine, acepromazine, meperidine, and xylazine on gastroesophageal sphincter pressure in the dog.
Harrold, D; Strombeck, DR, 1985
)
0.89

Toxicity

Propofol infusion is safe and shows no difference in outcome from the midazolam and meperidine sedation for the DBE procedure. Analgesic effects usually last 3-4 hours with parenteral administration.

ExcerptReferenceRelevance
"Sufentanil (R 30 730), N-[4-methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide, is a chemically novel, highly potent and extremely safe intravenous morphine-like agent in laboratory animals."( Sufentanil, a very potent and extremely safe intravenous morphine-like compound in mice, rats and dogs.
Janssen, PA; Niemegeers, CJ; Schellekens, KH; Van Bever, WF, 1976
)
0.26
"The influence of LD50 of lidocain by preliminary treatment with pethidin, aminophenazone or diazepam, respectively, is examined at the mouse."( [Over-additive increase of the toxicity of lidocaine by pethidine].
Lampe, D; Lange, B; Mai, I, 1976
)
0.26
" Significantly fewer patients treated with ketorolac reported adverse events in comparison with those treated with meperidine (17% and 59%, respectively), which suggests that it possesses a better therapeutic index than meperidine."( Comparison of the efficacy and safety of ketorolac and meperidine in the relief of dental pain.
Angelocci, D; Bynum, L; Fox, K; Fricke, JR; McHugh, D; Yee, JP, 1992
)
0.74
" With the large number of such procedures performed each year, even infrequent adverse anesthetic reactions may result in a significant number of problems."( Evaluation of safe, effective intravenous sedation for utilization in endoscopic procedures.
Andrus, CH; Dean, PA; Ponsky, JL, 1990
)
0.28
" We designed a study to evaluate the efficacy and adverse effects of diazepam and meperidine in combination for sedation in ambulatory pediatric patients undergoing endoscopy, colonoscopy, or liver biopsy."( Efficacy and safety of a diazepam and meperidine combination for pediatric gastrointestinal procedures.
Li, BU; Lininger, B; McClung, HJ; Murray, RD; Nahata, MC; Zingarelli, J, 1990
)
0.78
" lidocaine, as shown by marked reduction of LD50 by either opioid."( Opioid effects on lidocaine disposition and toxicity in mice.
Ben-Zvi, Z; Garty, M; Hurwitz, A, 1985
)
0.27
" The adverse effects of MPC were studied prospectively in 95 patients undergoing various procedures."( Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients.
Clotz, MA; Krogg, EA; Nahata, MC, 1985
)
0.6
"The purpose of this prospective study was to determine the frequency of adverse events associated with supplemented and unsupplemented chloral hydrate sedation in a select group of children undergoing CT or MR imaging using the revised American Academy of Pediatrics (AAP) monitoring and management guidelines for pediatric sedation."( Chloral hydrate sedation of children undergoing CT and MR imaging: safety as judged by American Academy of Pediatrics guidelines.
Dolenga, M; Habisohn-Schuck, C; Sukhani, R; Vade, A, 1995
)
0.29
"Use of supplemented and unsupplemented chloral hydrate sedation provides effective and safe sedation in children if the AAP guidelines for patient selection, monitoring, and management are followed."( Chloral hydrate sedation of children undergoing CT and MR imaging: safety as judged by American Academy of Pediatrics guidelines.
Dolenga, M; Habisohn-Schuck, C; Sukhani, R; Vade, A, 1995
)
0.29
" The safety profile was also studied by recording all adverse events noted."( Single-blind comparative analgesic and safety study of single doses of intramuscularly administered ketorolac tromethamine and pethidine hydrochloride in patients with pain following orthopaedic surgery.
Chhatwal, V; Kumar, VP; Lai, FO; Pereira, BP; Satku, K, 1994
)
0.29
" Adverse events were monitored and documented."( Safety assessment of high-dose narcotic analgesia for emergency department procedures.
Barsan, WG; Bartlett, R; Danzl, DF; Ling, LJ; Seger, D; Tomassoni, AJ, 1993
)
0.29
"This study of 72 patients demonstrates that high-dose narcotic analgesia is appropriate, well tolerated, and safe when used in selected patients before painful procedures in the ED."( Safety assessment of high-dose narcotic analgesia for emergency department procedures.
Barsan, WG; Bartlett, R; Danzl, DF; Ling, LJ; Seger, D; Tomassoni, AJ, 1993
)
0.29
" Analgesic effects usually last 3-4 hours with parenteral administration, and some adverse effects such as nausea may be reduced when meperidine is combined with antiemetic or antihistaminic medications."( Meperidine: therapeutic use and toxicity.
Anderson, PO; Clark, RF; Wei, EM,
)
1.78
"Cardiopulmonary adverse effects are commonly observed in patients undergoing colonoscopy with sedation."( Complications and adverse effects of colonoscopy with selective sedation.
Bernhard, G; Eckardt, AJ; Eckardt, VF; Kanzler, G; Schmitt, T, 1999
)
0.3
" Additional adverse effects occurring during or after the procedure were noted in the patients' protocol."( Complications and adverse effects of colonoscopy with selective sedation.
Bernhard, G; Eckardt, AJ; Eckardt, VF; Kanzler, G; Schmitt, T, 1999
)
0.3
" Adverse effects occurred in 59 patients (2."( Complications and adverse effects of colonoscopy with selective sedation.
Bernhard, G; Eckardt, AJ; Eckardt, VF; Kanzler, G; Schmitt, T, 1999
)
0.3
" If selective sedation is used, cardiopulmonary adverse effects occur in approximately 2% of all patients, most of whom require no medical intervention."( Complications and adverse effects of colonoscopy with selective sedation.
Bernhard, G; Eckardt, AJ; Eckardt, VF; Kanzler, G; Schmitt, T, 1999
)
0.3
"Because of the well known adverse effects that may be associated with pethidine use, the authors recommend that morphine should be the preferred agent in suspected renal colic, when an opioid analgesic is to be used."( A comparison of the efficacy and safety of morphine and pethidine as analgesia for suspected renal colic in the emergency setting.
Cardwell, H; O'Connor, A; Schug, SA, 2000
)
0.31
" Peribulbar block appears to be a safe and useful analgesic technique for paediatric ophthalmic surgery."( Safety and efficacy of peribulbar block as adjunct to general anaesthesia for paediatric ophthalmic surgery.
Deb, K; Dehran, M; Shende, D; Subramaniam, R; Tandon, R, 2001
)
0.31
"The authors report on adverse events and sedation outcomes for an oral sedation regimen of chloral hydrate, meperidine and hydroxyzine with 100 percent oxygen, or O2, supplementation."( Adverse events and outcomes of conscious sedation for pediatric patients: study of an oral sedation regimen.
Leelataweedwud, P; Vann, WF, 2001
)
0.52
" The authors analyzed age, sex, weight, methods of drug delivery, waiting time after drug administration, treatment rendered, treatment time, adverse events, sedation outcomes and the number of visits needed to complete treatment using descriptive statistics, chi 2 tests, t test and analysis of variance."( Adverse events and outcomes of conscious sedation for pediatric patients: study of an oral sedation regimen.
Leelataweedwud, P; Vann, WF, 2001
)
0.31
"Minimal minor adverse events occurred with this sedation regimen."( Adverse events and outcomes of conscious sedation for pediatric patients: study of an oral sedation regimen.
Leelataweedwud, P; Vann, WF, 2001
)
0.31
"This oral sedation regimen offers reasonable outcomes with minimal adverse events under a strict protocol and use of O2 supplementation."( Adverse events and outcomes of conscious sedation for pediatric patients: study of an oral sedation regimen.
Leelataweedwud, P; Vann, WF, 2001
)
0.31
" It is also safe and effective at the dosage studied in children undergoing MRI."( Efficacy and safety of rectal thiopental, intramuscular cocktail and rectal midazolam for sedation in children undergoing neuroimaging.
Alp, H; Altinkaynak, S; Güler, I; Orbak, Z, 2002
)
0.31
"Conscious intravenous sedation is a safe alternative method to general anaesthesia."( Continuous intravenous versus bolus parenteral midazolam: a safe technique for conscious sedation in plastic surgery.
Arscott, G; Bayat, A, 2003
)
0.32
"The combination of midazolam and ketamine appears to provide safe and effective sedation for pediatric patients undergoing endoscopy."( Safety and effectiveness of ketamine as a sedative agent for pediatric GI endoscopy.
Dietrich, CL; Gilger, MA; Spearman, G; Spearman, RS; Wilsey, MJ; Zayat, MN, 2004
)
0.32
" Study outcome measures evaluated the level of sedation, length of procedure, sedation/recovery time, patient satisfaction, and adverse events."( A prospective safety study of a low-dose propofol sedation protocol for colonoscopy.
Baluyut, A; Scheidler, M; Sipe, BW; Wright, B, 2007
)
0.34
" No serious adverse events occurred."( A prospective safety study of a low-dose propofol sedation protocol for colonoscopy.
Baluyut, A; Scheidler, M; Sipe, BW; Wright, B, 2007
)
0.34
"This protocol for propofol administration is safe and effective for patients undergoing elective colonoscopy."( A prospective safety study of a low-dose propofol sedation protocol for colonoscopy.
Baluyut, A; Scheidler, M; Sipe, BW; Wright, B, 2007
)
0.34
" The current practice of conscious sedation is safe and tolerated well by most adults in our population."( Tolerance and safety to colonoscopy with conscious sedation in Malaysian adults.
Goh, KL; Ma, WT; Mahadeva, S; Quek, KF, 2007
)
0.34
" The results of our study suggest that preoperative ITM combined with IV-PCA may be considered as an effective and safe pain management regimen in living liver donors who have characteristics of low tolerance to pain and postoperative coagulation derangement."( Intrathecal morphine combined with intravenous patient-controlled analgesia is an effective and safe method for immediate postoperative pain control in live liver donors.
Ahn, HJ; Cho, HS; Choi, SJ; Gwak, MS; Hahm, TS; Joh, JW; Kim, GS; Kim, JA; Kim, KM; Ko, JS, 2009
)
0.35
"Periprostatic plexus blocked with lidocaine does not offer advantages respect to meperidine, despite the fact that this is a safe method that does not increase the number of complications."( [Comparative study between analgesic efficacy and safety of meperidine compared with lidocaine periprostatic infiltration in transrectal ultrasound guided prostate biopsy].
Arlandis Guzmán, S; Bahílo Mateu, P; Bango García, V; Di Capua Sacoto, C; Jiménez Cruz, JF; Luján Marco, S; Ramírez Backhaus, M; Trassierra Villa, M, 2009
)
0.82
" Any adverse clinical effects such as somnolence, dizziness, nausea or vomiting were recorded."( Efficacy and safety of transnasal butorphanol for pain relief after anal surgery.
Chou, YC; Hsiao, CW; Jao, SW; Mai, CM; Wan, LT; Wu, CC; Yang, HY, 2009
)
0.35
" Length of hospital stay and the incidence of adverse effects between the groups were similar."( Efficacy and safety of transnasal butorphanol for pain relief after anal surgery.
Chou, YC; Hsiao, CW; Jao, SW; Mai, CM; Wan, LT; Wu, CC; Yang, HY, 2009
)
0.35
"Tubeless PCNL in selected patients with previous open nephrolithotomy has a safe and effective advantage compared to standard PCNL as indicated by a decrease in length of hospital stay and analgesic usage."( Does previous open nephrolithotomy affect the efficacy and safety of tubeless percutaneous nephrolithotomy?
Lojanapiwat, B, 2010
)
0.36
"Retrograde ileoscopy via stoma is a safe and effective procedure for evaluating recurrence of CD of the neoterminal ileum."( Ileoscopy via stoma after diverting ileostomy: a safe and effective tool to evaluate for Crohn's recurrence of neoterminal ileum.
Alkhouri, N; Lopez, R; Mahajan, L; Shen, B; Vadlamudi, N, 2011
)
0.37
"57% of patients having complications (52 patients having 60 adverse events)."( Safety of intravenous sedation administered by the operating oral surgeon: the second 7 years of office practice.
Rodgers, MS; Rodgers, SF, 2011
)
0.37
"This study determined the quality of perioperative analgesia and side effect profile of spinal bupivacaine plus pethidine for caesarean section."( Subarachnoid bupivacaine and pethidine for caesarean section: assessment of quality of perioperative analgesia and side effects.
Akhideno, II; Akpoguado, DD; Asudo, FD; Imarengiaye, CO; Ogunsakin, AT; Omoifo, CE, 2011
)
0.37
"5mg resulted in better quality of anaesthesia, longer postoperative analgesia with acceptable side effect profile."( Subarachnoid bupivacaine and pethidine for caesarean section: assessment of quality of perioperative analgesia and side effects.
Akhideno, II; Akpoguado, DD; Asudo, FD; Imarengiaye, CO; Ogunsakin, AT; Omoifo, CE, 2011
)
0.37
"In case of endoscopically difficult-to-treat pancreatic duct stones, combined therapy with ESWL is an effective method, and treatment with multiple sessions of ESWL on successive days under intravenous bolus of pethidine alone is safe and well tolerated."( [Safety and effectiveness of successive extracorporeal shock wave lithotripsy for pancreatolithiasis under intravenous bolus pethidine administration alone].
Choi, JH; Kim, HJ; Kim, MH; Lee, BU; Lee, SK; Lee, SS; Park, DH; Seo, DW, 2014
)
0.4
" Proper management of the untoward effects of this method may introduce it as a safe and low-cost method for painless labor."( Efficacy and Safety of Sufentanil and Pethidine in Spinal Anesthesia for Painless Labor.
Bagheri, B; Farzanegan, B; Fathi, M; Salarian, S, 2015
)
0.42
" We aim to determine whether the administration of propofol infusion is safe by comparing it to intravenous midazolam/meperidine in patients undergoing DBE."( The safety of propofol infusion compared to midazolam and meperidine intravenous bolus for patients undergoing double balloon enteroscopy.
Angsuwatcharakon, P; Kongkam, P; Ponuthai, Y; Rerknimitr, R; Ridtitid, W; Thanapirom, K; Treeprasertsuk, S; Viriyautsahakul, V, 2014
)
0.86
"Propofol infusion is safe and shows no difference in outcome from the midazolam and meperidine sedation for the DBE procedure."( The safety of propofol infusion compared to midazolam and meperidine intravenous bolus for patients undergoing double balloon enteroscopy.
Angsuwatcharakon, P; Kongkam, P; Ponuthai, Y; Rerknimitr, R; Ridtitid, W; Thanapirom, K; Treeprasertsuk, S; Viriyautsahakul, V, 2014
)
0.87
"The study investigated patient discharge parameters and postdischarge adverse events after discharge among children who received oral conscious sedation for dental treatment."( Oral Sedation Postdischarge Adverse Events in Pediatric Dental Patients.
Huang, A; Tanbonliong, T, 2015
)
0.42
"This trial aimed to ascertain the relative efficacy, adverse effects, and acceptability of fentanyl versus pethidine for pain relief during labour."( The safety and acceptability of intravenous fentanyl versus intramuscular pethidine for pain relief during labour.
Dawood, R; El-Shamy, ES; Habeeb, R; Massod, A; Rezk, M, 2015
)
0.42
" Pain scores hourly, maternal and fetal adverse effects, neonatal outcome, and maternal acceptability were assessed."( The safety and acceptability of intravenous fentanyl versus intramuscular pethidine for pain relief during labour.
Dawood, R; El-Shamy, ES; Habeeb, R; Massod, A; Rezk, M, 2015
)
0.42
" The Institute for Safe Medication Practices has suggested avoiding meperidine in older adults, limiting its dose (≤600 mg/day) and duration of use (≤48 h)."( The safety of meperidine prescribing in older adults: A longitudinal population-based study.
Bugden, S; Falk, J; Friesen, KJ, 2016
)
1.03
"The risks of minor adverse events (MAEs) such as abdominal pain and bloating after colon polypectomy (CP) are less clearly documented than major adverse events."( Prospective Analysis of Minor Adverse Events After Colon Polypectomy.
Choi, KY; Chun, HK; Jeong, KU; Jeong, SH; Jung, YS; Kim, H; Kim, HO; Lee, MG; Park, DI; Park, SK; Yang, HJ, 2017
)
0.46
" Maternal adverse effects of Pethilorfan were generally mild and transient."( Safety and efficacy of a combination of pethidine and levallorphan for pain relief during labor: An observational study.
Kinugasa, M; Miyake, M; Tamai, H; Tamura, M, 2019
)
0.51
"Randomized controlled trials that compared the analgesic efficacy and side effect profile of meperidine versus another analgesic drug in adult patients were evaluated."( Analgesic Efficacy and Adverse Effects of Meperidine in Managing Postoperative or Labor Pain: A Narrative Review of Randomized Controlled Trials.
Cheung, CW; Ching Wong, SS, 2020
)
1.04
"Acute postoperative pain, adverse effects, labor analgesia, meperidine, pethidine."( Analgesic Efficacy and Adverse Effects of Meperidine in Managing Postoperative or Labor Pain: A Narrative Review of Randomized Controlled Trials.
Cheung, CW; Ching Wong, SS, 2020
)
1.06
"The number of therapeutic endoscopic procedures in elderly individuals keeps increasing and this population has a high risk of adverse events related to sedation and general anesthesia."( Efficacy and safety of endoscopic retrograde cholangiopancreatography in the very elderly by using a combination of intravenous midazolam, ketamine and pethidine.
Cetin, MF; Tokmak, S; Torun, S, 2021
)
0.62
"Reviews of the sedation logs of 1,785 sedation visits are compared with emphasis on what dosing proves both safe and effective for differing levels of challenging pediatric behavior."( Retrospective Comparisons of the Efficacy and Safety of Variable dosing of Midazolam with and without Meperidine for Management of Varying Levels of Anxiety of Pediatric Dental Patients: 35 years of Sedation Experience.
Nathan, JE, 2022
)
0.94
"Where Mep was used, success rates were consistently higher; working times were significantly prolonged and greater control was provided to avoid adverse reactions by virtue of reversal capability for both agents."( Retrospective Comparisons of the Efficacy and Safety of Variable dosing of Midazolam with and without Meperidine for Management of Varying Levels of Anxiety of Pediatric Dental Patients: 35 years of Sedation Experience.
Nathan, JE, 2022
)
0.94
"5 mg/kg Mep offers the most effective and safe results to overcome need for restraint for moderate and severe levels of anxiety, respectively."( Retrospective Comparisons of the Efficacy and Safety of Variable dosing of Midazolam with and without Meperidine for Management of Varying Levels of Anxiety of Pediatric Dental Patients: 35 years of Sedation Experience.
Nathan, JE, 2022
)
0.94

Pharmacokinetics

The aim of this study was to determine whether the addition of a small dose of prilocaine could augment the spinal block induced by meperidine. Meperidine elimination half-life fell from 6.5 to 10. The short half- life and lack of detectable antinociceptive effect do not support IM or subcutaneous administration me peridine at 1 mg/kg for analgesia.

ExcerptReferenceRelevance
" When the pharmacokinetic data were compared with the time course of analgesia, the plasma levels of pethidine could be correlated with the analgesic effect after the first rapid distribution phase."( Pharmacokinetics and analgesic effect of pethidine (meperidine) and its metabolites in the rat.
Bogentoft, C; Dahlström, BE; Lindberg, C; Paalzow, LK,
)
0.38
"The aim of this study was to determine whether the addition of a small dose of prilocaine could augment the spinal block induced by meperidine and affect intrathecal meperidine pharmacokinetic behaviour."( Clinical and pharmacokinetic aspects of the combination of meperidine and prilocaine for spinal anaesthesia.
Bonnet, F; Hecquet, D; Houdek, MC; Maurette, P; Tauzin-Fin, P; Vincon, G, 1992
)
0.73
" The pharmacokinetics of meperidine varied greatly between the subjects, with a median elimination half-life of 10."( Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants.
Koivisto, M; Olkkola, KT; Pokela, ML; Ryhänen, P, 1992
)
0.84
" No apparent ethnic differences were found in the tmax and Cmax of norpethidine which emerged as the major metabolite in the plasma in the three races."( Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients.
Aun, CS; Chan, K; Houghton, IT; Lau, OW; Lowe, DM; Wong, YC,
)
0.13
" Drug uptake and retention in extravisceral tissues, represented here by the hindquarters, can result in the mean total body drug clearance being overestimated when determined by traditional systemic pharmacokinetic methods."( Uptake and elution of chlormethiazole, meperidine, and minaxolone in the hindquarters of sheep: implications for clearance calculations.
Carapetis, RJ; Mather, LE; McLean, CF; Runciman, WB; Upton, RN, 1991
)
0.55
" When the drug was given intravenously (2 mg kg-1), plasma levels declined in a biexponential manner, with an elimination half-life of 62."( Pharmacokinetics of pethidine administered intramuscularly and intravenously to dogs over 10 years old.
Kalthum, W; Waterman, AE, 1990
)
0.28
" Values of elimination half-life ranged from 13."( Pharmacokinetics of propofol when given by intravenous infusion.
Campbell, GA; Crankshaw, DP; Morgan, DJ, 1990
)
0.28
" These pharmacokinetic constants calculated on data collected through 48 h in this study may have important clinical correlates."( Pharmacokinetics of meperidine in pregnancy.
Bucovaz, ET; Morrison, JC; Stafford, DT; Todd, EL, 1989
)
0.6
" The terminal plasma half-life averaged 91 +/- 34 min and 87 +/- 27 min, respectively (mean +/- SEM)."( Pharmacokinetics of epidural morphine and meperidine in humans.
Hartvig, P; Persson, MP; Sjöström, S; Tamsen, A, 1987
)
0.54
" After a rapid initial decline for about 15 min after injection, the CSF concentrations decreased with a half-life of 89."( Pharmacokinetics of intrathecal morphine and meperidine in humans.
Hartvig, P; Persson, MP; Sjöström, S; Tamsen, A, 1987
)
0.53
" The CSF morphine concentration, measured as the area under the CSF concentration curve (AUC), the maximal CSF concentration (Cmax) and the time to reach maximal CSF concentration (tmax), varied between the four groups."( Pharmacokinetics of different epidural sites of morphine administration.
Hansdottir, V; Hedner, T; Kvist, L; Mellstrand, T; Nordberg, G, 1987
)
0.27
" The pharmacokinetic data suggests that intrathecal meperidine provides prolonged postoperative analgesia through a regional effect on opioid receptors in the spinal cord."( Pharmacokinetics of meperidine in spinal anaesthesia.
Absood, A; Famewo, CE; Naguib, M, 1986
)
0.85
" Unfortunately, there have been few pharmacokinetic studies in trauma patients."( The pharmacokinetics of meperidine in acute trauma patients.
Edwards, DJ; Hassett, JM; Kirkwood, CF; Lalka, D; Lasezkay, G; Slaughter, RL, 1986
)
0.58
" The mean plasma half-life of elimination (t1/2 beta) was about the same following oral (2."( Clinical pharmacokinetics and oral bioavailability of ketobemidone.
Anderson, P; Arnér, S; Bondesson, U; Boréus, LO; Hartvig, P, 1980
)
0.26
"50 mg morphine intrathecally (L2-L3 or L3-L4) for an analgetic and pharmacokinetic study."( Pharmacokinetic aspects of intrathecal morphine analgesia.
Dahlström, B; Hedner, T; Mellstrand, T; Nordberg, G, 1984
)
0.27
" The NONLIN program was used to calculate pharmacokinetic parameters for each individual."( Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods.
Dahlström, B; Fagerlund, C; Hartvig, P; Tamsen, A,
)
0.13
" These studies confirm the importance of clinical pharmacokinetic measurements in the investigation and treatment of patients with intractable pain."( Clinical pharmacokinetics applied to patients with intractable pain: studies with pethidine.
Glynn, CJ; Mather, LE, 1982
)
0.26
" 3 Other model-dependent pharmacokinetic parameters were consistent with previously reported values."( Pethidine clearance during continuous intravenous infusions in postoperative patients.
Austin, KL; Mather, LE; Stapleton, JV, 1981
)
0.26
"The pharmacokinetic constants and rectal bioavailability of the narcotic analgesic ketobemidone were determined in six male patients after surgery."( Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration.
Anderson, P; Arnér, S; Bondesson, U; Boréus, LO; Hartvig, P, 1981
)
0.26
" Plasma concentration data were fitted to a biexpoential equation and pharmacokinetic parameters were calculated."( A comparison of alphaprodine and meperidine pharmacokinetics.
Asling, JH; Eisele, JH; Fung, DL; Martucci, R, 1980
)
0.54
"34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
"We could not show any statistically significant influence of an epidural blockade on the pharmacokinetic parameters of propofol."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
" Pharmacokinetic parameters were calculated according to standard techniques."( Pharmacokinetics and local responses to submucosal meperidine compared with other routes of administration.
Burckart, G; Habucky, K; McKee, KC; Nazif, MM; Schmitt, M; Venkataramanan, R; Zullo, T,
)
0.38
"Pharmacokinetic (based on concentration-time curves) and pharmacodynamic (i."( Site-specific pharmacokinetics and pharmacodynamics of intramuscular meperidine in elderly postoperative patients.
Chow, HH; Erstad, BL; Levinson, ML; Meeks, ML; Rappaport, WD, 1997
)
0.53
" Substantial interpatient variability in pharmacokinetic parameters was noted for both sites (range of maximum concentrations: 191-500 ng/mL gluteal, 166-374 ng/mL deltoid)."( Site-specific pharmacokinetics and pharmacodynamics of intramuscular meperidine in elderly postoperative patients.
Chow, HH; Erstad, BL; Levinson, ML; Meeks, ML; Rappaport, WD, 1997
)
0.53
"There is no obvious relationship between meperidine pharmacokinetic and pharmacodynamic parameters, regardless of intramuscular injection site."( Site-specific pharmacokinetics and pharmacodynamics of intramuscular meperidine in elderly postoperative patients.
Chow, HH; Erstad, BL; Levinson, ML; Meeks, ML; Rappaport, WD, 1997
)
0.8
"Open-label, crossover, pharmacokinetic study."( The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine.
Bertz, RJ; Davey, R; Kress, DR; Pau, A; Piscitelli, SC, 2000
)
0.56
" The pharmacokinetic analysis was performed using WinNonlin trade mark software."( The pharmacokinetics of ketobemidone in critically ill patients.
Al-Shurbaji, A; Tokics, L, 2002
)
0.31
"There was a wide variation in the different pharmacokinetic parameters among patients."( The pharmacokinetics of ketobemidone in critically ill patients.
Al-Shurbaji, A; Tokics, L, 2002
)
0.31
"Physiologically based pharmacokinetic (PBPK) models can be used to predict drug disposition in humans from animal data and the influence of disease or other changes in physiology on the pharmacokinetics of a drug."( Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models.
Björkman, S, 2003
)
0.32
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Pharmacokinetic parameters were determined using compartmental methods."( Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children.
Eksborg, S; Lafolie, P; Lundeberg, S; Olsson, GL; Stephanson, N; Stiller, CO, 2010
)
0.36
"Six children were excluded from pharmacokinetic analysis because of incomplete blood sampling."( Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children.
Eksborg, S; Lafolie, P; Lundeberg, S; Olsson, GL; Stephanson, N; Stiller, CO, 2010
)
0.36
"The pharmacokinetic parameters of ketobemidone in children older than 1 month appear to be similar to those in adults."( Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children.
Eksborg, S; Lafolie, P; Lundeberg, S; Olsson, GL; Stephanson, N; Stiller, CO, 2010
)
0.36
" In an earlier study, we have examined the pharmacokinetic properties in children in different age groups but have not focused on neonates."( Pharmacokinetics after a single intravenous dose of the opioid ketobemidone in neonates.
Eksborg, S; Lundeberg, S; Stephanson, N; Stiller, CO, 2012
)
0.38
" Pharmacokinetic parameters were calculated with standard compartmental methods."( Pharmacokinetics after a single intravenous dose of the opioid ketobemidone in neonates.
Eksborg, S; Lundeberg, S; Stephanson, N; Stiller, CO, 2012
)
0.38
" Despite a low pharmacokinetic variability of ketobemidone as observed in the present neonatal patient population, we recommend individualizing the dose of ketobemidone based on observations of analgesic efficacy."( Pharmacokinetics after a single intravenous dose of the opioid ketobemidone in neonates.
Eksborg, S; Lundeberg, S; Stephanson, N; Stiller, CO, 2012
)
0.38
" The peak concentration (Cmax) and area under the concentration-time curve (AUC) of pethidine and its metabolite norpethidine were significantly higher during the dark phase than during the light phase, but the total serum clearance (CL/F) exhibited the opposite trend."( Chronopharmacodynamics and chronopharmacokinetics of pethidine in mice.
Li, X; Liu, D; Xu, Y; Yu, Z; Zhang, C, 2014
)
0.4
" We estimated the apparent pharmacokinetic parameters for meperidine in oral fluid and plasma and determined the ratio and correlation between oral fluid and plasma concentrations."( Pharmacokinetics of meperidine (pethidine) in rabbit oral fluid: correlation with plasma concentrations after controlled administration.
Cao, J; Du, Y; Jia, J; Liang, W; Sun, JH; Wang, YJ; Wang, YY; Wei, ZW; Wu, B; Yun, KM, 2018
)
1.05
" Plasma meperidine concentrations and pharmacodynamic values (thermal and mechanical thresholds, physiological variables, fecal production) were collected at various time points for 24 hours."( Pharmacokinetics and pharmacodynamics of meperidine after intramuscular and subcutaneous administration in horses.
Barletta, M; Hanafi, AL; Knych, HK; Quandt, JE; Reed, RA; Ryan, CA; Sakai, DM; Trenholme, HN, 2021
)
1.32
"The short half-life and lack of detectable antinociceptive effect do not support IM or subcutaneous administration meperidine at 1 mg/kg for analgesia in horses."( Pharmacokinetics and pharmacodynamics of meperidine after intramuscular and subcutaneous administration in horses.
Barletta, M; Hanafi, AL; Knych, HK; Quandt, JE; Reed, RA; Ryan, CA; Sakai, DM; Trenholme, HN, 2021
)
1.1
" Physiologically based pharmacokinetic (PBPK) modeling can predict drug concentrations in newborn plasma, saliva, and bECF after intrauterine pethidine exposure."( The Analysis of Pethidine Pharmacokinetics in Newborn Saliva, Plasma, and Brain Extracellular Fluid After Prenatal Intrauterine Exposure from Pregnant Mothers Receiving Intramuscular Dose Using PBPK Modeling.
Alsmadi, MM; Idkaidek, N, 2023
)
0.91

Compound-Compound Interactions

Propofol alone and propofol in combination with meperidine are frequently used during colonoscopy. This study compared the analgesic efficacy, sedative, and amnesic properties, and side effects of nalbuphine versus me peridine as intravenous premedicants.

ExcerptReferenceRelevance
"Continuous Reaction Time (CRT) was measured in cancer patients receiving peripherally acting analgesics either alone (n = 16) or in combination with opioids (n = 16)."( Reaction time in cancer patients receiving peripherally acting analgesics alone or in combination with opioids.
Banning, A; Kaiser, F; Sjøgren, P, 1992
)
0.28
"The purpose of this study was to compare the effectiveness of a chloral hydrate/hydroxyzine combination with and without meperidine in the sedation of pediatric dental patients."( Comparison of a chloral hydrate/hydroxyzine combination with and without meperidine in the sedation of pediatric dental patients.
Farrington, FH; Mourino, AP; Poorman, TL,
)
0.57
"This study compared the analgesic efficacy, sedative, and amnesic properties, and side effects of nalbuphine versus meperidine as intravenous premedicants in combination with intravenous diazepam for the treatment of outpatients undergoing the removal of impacted third molars with alveolar nerve block anesthesia."( A double-blind comparison of nalbuphine and meperidine hydrochloride as intravenous analgesics in combination with diazepam for oral surgery outpatients.
Scott, RF, 1987
)
0.74
" doses of midazolam and diazepam in combination with meperidine on breathing pattern and thoracoabdominal motion were studied in eight healthy male volunteers."( Changes in breathing pattern and chest wall mechanics after benzodiazepines in combination with meperidine.
Berggren, L; Eriksson, I; Mollenholt, P, 1987
)
0.74
" We conclude that the effects of meperidine upon fetal heart rate characteristics are both potentiated by propiomazine, and, when meperidine is given with propiomazine, dose-related."( Fetal heart rate responses to meperidine alone and in combination with propiomazine.
Barrett, JM; Boehm, FH, 1983
)
0.84
"To determine the effect of chlorpromazine on the serum concentration-time curve and metabolism of meperidine, 10 healthy volunteers were injected on two separate days in a two-way crossover design with 26 mg/m2 meperidine hydrochloride combined with either 30 mg/m2 chlorpromazine or a placebo."( Drug interaction: meperidine and chlorpromazine, a toxic combination.
Stambaugh, JE; Wainer, IW, 1981
)
0.81
"To investigate the pharmacokinetics of propofol in combination with epidural anesthesia or with intravenous (i."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
" In Group 1, a continuous infusion of propofol was combined with an epidural block with bupivacaine."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
" Nevertheless, the concentration-time profile changed during infusion, rendering the described infusion regimen, in combination with epidural anesthesia, unsatisfactory for adequate hypnosis."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
"In this randomized, double-blinded study, we compared the onset and recovery characteristics of an investigational benzodiazepine, Ro 48-6791 (when administered alone or combined with meperidine), a midazolam-meperidine combination for sedation during gastrointestinal (GI) endoscopic procedures."( Comparison of the sedation and recovery profiles of Ro 48-6791, a new benzodiazepine, and midazolam in combination with meperidine for outpatient endoscopic procedures.
Gold, J; Gold, M; Tang, J; Wang, B; White, PF, 1999
)
0.7
"This study was performed to compare the effects of oral midazolam and oral diazepam, administered with intravenous (IV) meperidine, on pre-procedural, procedural, and post-procedural sedation and recovery in children undergoing diagnostic upper endoscopy."( A comparison of oral diazepam versus midazolam, administered with intravenous meperidine, as premedication to sedation for pediatric endoscopy.
Davis, J; Marquez, C; Martinez, JL; Medina, E; Merzel, D; Montano, N; Sutters, KA; Waite, S, 2002
)
0.75
" Therefore, intrathecal opioids combined with a low dose of epidural local anesthetics for Cesarean section is suitable for critically ill patients with malignant abdominal tumors, such as a Krukenberg tumor, complicated by massive ascites."( Intrathecal fentanyl/meperidine combined with low-dose epidural bupivacaine for Cesarean section in a patient with advanced Krukenberg tumors.
Amano, K; Hoka, S; Hoshino, Y; Okamoto, H; Okutomi, T, 2002
)
0.63
"There is currently a vast experience reported in the literature with respect to Propofol utilization as a single agent and in combination with narcotics and/or benzodiazepines in endoscopic procedures, without the presence of an anesthesiologist in the endoscopy suite."( [Propofol in combination with meperidine and midazolam in colonoscopy and upper endoscopy: first prospective study in private practice in Peru].
Ramos, M; Siu, H; Tagle, M,
)
0.42
"To report the experience in a private endoscopy center in Lima utilizing propofol in combination with Meperidine and Midazolam in colonoscopies and upper endoscopies, administered by a nurse supervised by a trained gastroenterologist without the presence of an anesthesiologist."( [Propofol in combination with meperidine and midazolam in colonoscopy and upper endoscopy: first prospective study in private practice in Peru].
Ramos, M; Siu, H; Tagle, M,
)
0.64
"Propofol combined with Meperine and Midazolam in endoscopic procedures is a safe agent administered by a trained gastroenterologist and nurse."( [Propofol in combination with meperidine and midazolam in colonoscopy and upper endoscopy: first prospective study in private practice in Peru].
Ramos, M; Siu, H; Tagle, M,
)
0.42
"We examined hemodynamic responses during gastroscopy in healthy subjects and compared the changes with midazolam alone versus in combination with meperidine."( Comparison of the effects of intravenous midazolam alone and in combination with meperidine on hemodynamic and respiratory responses and on patient compliance during upper gastrointestinal endoscopy: a randomized, double-blind trial.
Demirtürk, L; Gürbüz, AK; Oncü, K; Ozel, AM; Yazgan, Y, 2008
)
0.77
" Both propofol alone and propofol in combination with meperidine are frequently used during colonoscopy, but the impact of adding meperidine has not been evaluated."( Propofol alone versus propofol in combination with meperidine for sedation during colonoscopy.
Chang, YL; Chen, BS; Chen, IC; Chou, AL; Hsieh, YH; Lai, YY; Lin, HJ; Sia, SL, 2009
)
0.85
"For sedated colonoscopy, propofol in combination with meperidine is better than propofol alone in improving patients' tolerance and recovery."( Propofol alone versus propofol in combination with meperidine for sedation during colonoscopy.
Chang, YL; Chen, BS; Chen, IC; Chou, AL; Hsieh, YH; Lai, YY; Lin, HJ; Sia, SL, 2009
)
0.85
" This study compared, in donor right hepatectomy, the efficacy and safety of preoperative intrathecal morphine (ITM) combined with intravenous patient-controlled analgesia (IV-PCA) with IV-PCA alone."( Intrathecal morphine combined with intravenous patient-controlled analgesia is an effective and safe method for immediate postoperative pain control in live liver donors.
Ahn, HJ; Cho, HS; Choi, SJ; Gwak, MS; Hahm, TS; Joh, JW; Kim, GS; Kim, JA; Kim, KM; Ko, JS, 2009
)
0.35
" This study to evaluate the effect of dexmedetomidine combined with sufentanil for PCIA after thoracotomy under general anaesthesia."( Effect of Dexmedetomidine combined with sufentanil for post- thoracotomy intravenous analgesia:a randomized, controlled clinical study.
Dong, CS; Lu, Q; Sun, H; Sun, P; Wu, C; Yu, JM; Zhang, J, 2017
)
0.46
"Comparing bupivacaine's adjuvants in spinal anesthesia, we assessed the specific blocking characteristics and adverse effects of bupivacaine alone and in combination with dexmedetomidine or meperidine in spinal anesthesia during cesarean section."( Analgesic Characteristics of Bupivacaine Alone and in Combination with Dexmedetomidine or Meperidine in Spinal Anesthesia during Cesarean Section: A Double-Blind Randomized Clinical Trial Study.
Azemati, S; Jouybar, R; Naderi-Boldaji, V; Zarghami, A, 2022
)
1.13

Bioavailability

Systemic clearance of meperidine was smaller and bioavailability and half-life greater in the cirrhotic patients than in the normal subjects. These findings may be explained in part by prolongation ofmeperidine bioavailability because of impairment of hepatic function.

ExcerptReferenceRelevance
"The effect of moderate cirrhosis on the bioavailability and systemic clearance of three model analgesic compounds (pethidine, pentazocine, and salicylamide) with substantial first-pass metabolism was examined in 8 cirrhotic subjects and 4 agematched healthy controls."( Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis.
Blaschke, TF; Gregory, PB; Meffin, PJ; Neal, EA, 1979
)
0.26
" The use of the urinary excretion pattern and concentrations represents a rapid, accurate, and quantitative method for determining the bioavailability of different preparations of meperidine hydrochloride."( The bioavailability of meperidine using urine assays for meperidine and normeperidine.
Stambaugh, JE; Wainer, IW, 1975
)
0.76
"The rate of absorption and plasma concentrations of lidocaine were determined in 15 supine patients under general anesthesia following either endotracheal spray of 200 mg."( Plasma concentration of lidocaine after endotracheal spray.
Brannan, MD; Chu, SS; Cohen, JL; Rah, KH,
)
0.13
" When the drug was given intramuscularly its rate of absorption was very slow (57."( The effect of clinical hepatic disease on the distribution and elimination of pethidine administered post-operatively to dogs.
Kalthum, W; Waterman, AE, 1990
)
0.28
" (2) Since in the low frequency range the drugs exhibited contrary effects upon spontaneous and evoked EEG activity, the pre-/post-stimulus relationship of the delta power was found to be the most sensitive measure for monitoring the cerebral bioavailability of the tested drugs."( Pre-stimulus/post-stimulus relations in EEG spectra and their modulations by an opioid and an antidepressant.
Bromm, B; Meier, W; Scharein, E, 1989
)
0.28
"3 h and 14 min, respectively), but systemic bioavailability was similar."( CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine.
Bondesson, U; Boréus, LO; Hansdottir, V; Hedner, T; Mellstrand, T; Nordberg, G, 1988
)
0.27
"90 (SD) and the mean relative bioavailability of the mixture was slightly above 100%."( Analgesic effect and bioavailability of oral ketogan given as tablets or mixture to patients with chronic pain of malignant origin.
Kjaer, M; Nielsen, H, 1988
)
0.27
" Gastric emptying in the immediate postoperative period was also assessed in each patient by measuring the rate of absorption of orally administered paracetamol."( Analgesic and gastrointestinal effects of nalbuphine--a comparison with pethidine.
Couch, RA; Mark, A; Slattery, PJ, 1986
)
0.27
"The basic pharmacokinetics and oral bioavailability of ketobenmidone have been studied in 6 patients after surgery."( Clinical pharmacokinetics and oral bioavailability of ketobemidone.
Anderson, P; Arnér, S; Bondesson, U; Boréus, LO; Hartvig, P, 1980
)
0.26
"The single-dose kinetics and the oral and rectal bioavailability of ketobemidone have been studied in patients after surgery."( Single-dose kinetics and bioavailability of ketobemidone.
Anderson, P; Arnér, S; Bondesson, U; Boréus, LO; Hartvig, P, 1982
)
0.26
"We studied the bioavailability and disposition kinetics of pethidine and pentazocine in patients with alcoholic cirrhosis and age-matched healthy subjects."( Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver.
Benowitz, NL; Jacob, P; Pond, SM; Tong, T, 1980
)
0.26
" In the third patient, whose eneral bioavailability was only 20%, the MEAC was not obtained."( Clinical pharmacokinetics applied to patients with intractable pain: studies with pethidine.
Glynn, CJ; Mather, LE, 1982
)
0.26
"The pharmacokinetic constants and rectal bioavailability of the narcotic analgesic ketobemidone were determined in six male patients after surgery."( Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration.
Anderson, P; Arnér, S; Bondesson, U; Boréus, LO; Hartvig, P, 1981
)
0.26
" Systemic clearance of meperidine was smaller and bioavailability and half-life greater in the cirrhotic patients than in the normal subjects."( Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects.
Benowitz, NL; Jacob, P; Pond, SM; Rigod, J; Tong, T, 1981
)
0.87
" In contrast, oral bioavailability was incomplete, ranging from 47% to 73%, and at a much slower rate, with peak concentrations being observed after about 1 hr."( Meperidine disposition in man: influence of urinary pH and route of administration.
Branch, RA; Verbeeck, RK; Wilkinson, GR, 1981
)
1.71
" These findings may be explained in part by prolongation of meperidine bioavailability because of impairment of hepatic function."( Meperidine in conjunction with cholescintigraphy to diagnose acute cholecystitis in a patient allergic to morphine.
Fong, J; Gora, ML; Shih, WJ, 1994
)
1.97
" The mean systemic bioavailability after rectal administration was approximately 55%."( Pharmacokinetics of i.v. and rectal pethidine in children undergoing ophthalmic surgery.
Hamunen, K; Maunuksela, EL; Olkkola, KT; Seppälä, T, 1993
)
0.29
" Elimination rate constant (lambda z) and clearance uncorrected for bioavailability (Cl/F) were significantly lower at high altitudes than at sea level in plasma (HA and HC) and in whole blood (HA only)."( Pharmacokinetics of meperidine in healthy volunteers after short- and long-term exposure to high altitude.
Agrawal, MA; Arancibia, A; Lücker, PW; Paulos, C; Pezzani, M; Ritschel, WA; Wetzelsberger, KM, 1996
)
0.62
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31

Dosage Studied

This case report demonstrates the successful management of the patient with analgesia provided by a continuous spinal catheter dosed with a continuous infusion of fentanyl. Using the described intravenous dosing schedule, fentanyl was preferable to meperidine during labor because there was no prolonged maternal sedation or vomiting necessitating therapy.

ExcerptRelevanceReference
" The incidence of tracheal soiling was lower than that with other intravenous techniques and could be attributed to the use of the semisupine position or the baseline concept of narcotic dosage in the Jorgensen technique."( The efficacy of the laryngeal reflex in conscious sedation.
Allen, GD; Jorgensen, NB; Ricks, CS, 1977
)
0.26
" There was no significant difference between the mothers and babies in the three meperidine dosage groups for maternal parity, maternal age, birth weight, number of forceps deliveries or duration of labour."( Double-blind comparison of the neurobehaviour of neonates following the administration of different doses of meperidine to the mother.
Bhatt, M; Hodgkinson, R; Wang, CN, 1978
)
0.7
"Twenty opioids have been subdivided into four classes by using flurothyl-induced seizures in rats to measure dose-response relationships, stereospecificity, naloxone sensitivity, and tolerance-cross-tolerance."( Classification of opioids on the basis of change in seizure threshold in rats.
Adler, MW; Cowan, A; Geller, EB, 1979
)
0.26
" Administration of a standard premedication dosage to patients sedated for other reasons occasionally led to worsened respiratory status; pre-medication should be reduced or eliminated in sedated patients."( Bronchofiberscopy in the postoperative management of lung surgery patients.
Nakhosteen, JA, 1979
)
0.26
" Naloxone caused a parallel shift to the right of the dose-response curve for morphine."( Inhibition by morphine of prostaglandin-stimulated fluid secretion in rat jejunum.
Coupar, IM, 1978
)
0.26
" The effect of acetylcholine is also significantly potentiated by pretreatment with 6-hydroxydopamine or denervation, but not by reserpine, while the dose-response curve for carbachol is not affected by the specific cholinesterase inhibitor BW 284 C51, denervation or 6-hydroxydopamine."( Uptake and release of catecholamines in sympathetic nerve fibers in the spleen of the cod, Gadus morhua.
Holmgren, S; Nilsson, S, 1976
)
0.26
" By utilizing the drugs discussed and titrating the dosage to the needs of the patient, intravenous sedation will last long enough to complete the selected periodontal surgical procedure."( Intravenous sedation of the periodontal surgical patient.
Ruggerio, AC, 1975
)
0.25
" The urinary excretion patterns resulting from dosing with the two preparations were followed for 48 hours, and the urine concentrations of meperidine and a major metabolite, normeperidine, were determined by gas liquid chromatography."( The bioavailability of meperidine using urine assays for meperidine and normeperidine.
Stambaugh, JE; Wainer, IW, 1975
)
0.77
" A parallelism between the dosage of the substances and the intensity of the analgetic effect and the degree of changed permeability of the blood-cerebral barrier could be noted."( [Effect of promedol and fentanyl on the permeability of the hemato-encephalic barrier of rats for noradrenaline-H3].
Raevskiĭ, KS; Romanova, EA; Tolmacheva, NS,
)
0.13
" From the data it appears that in the case of acute pain, the intramuscular route of administration is as beneficial as the intravenous route, that oral dosing is less efficacious due to lower peak serum concentrations, and that all doses, regardless of the route administration, should be administered clinically on a mg/m2 basis rather than as a predetermined dose as currently used."( The clinical pharmacology of meperidine--comparison of routes of administration.
Hemphill, DM; Sanstead, JK; Stambaugh, JE; Wainer, IW,
)
0.42
" After evaluation during 12 h with Ketogan tablets (3-4 dosing intervals), a loading phase lasting for 36 h with cetobem."( Bioavailability and analgesic effect of sustained release cetobemidone capsules in cancer patients with chronic pain of malignant origin.
Andersen, LS; Kjaer, M; Nielsen, H; Olsen, FE; Philipsen, J; Velander, G, 1992
)
0.28
" Caution may be required on multiple dosing of pethidine in Asian patients due to the possible accumulation of the parent drug and its toxic metabolite, norpethidine."( Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients.
Aun, CS; Chan, K; Houghton, IT; Lau, OW; Lowe, DM; Wong, YC,
)
0.13
" The first dosage was 100 mg of all substances."( [Use of tramadol versus pethidine versus denaverine suppositories in labor--a contribution to noninvasive therapy of labor pain].
Bredow, V, 1992
)
0.28
" Chloral hydrate in dosages of 25 mg/kg to 100 mg/kg is the most common drug used for sedation; DPT, a combination of parenteral Demerol (meperidine), Phenergan (promethazine), and Thorazine (chlorpromazine), at a maximum dose of 2 mg/1 mg/1 mg/kg is the second; and pentobarbital in a dosage of 5 mg/kg to 7 mg/kg is the third."( Sedation of children for technical procedures: current standard of practice.
Alexander, ME; Bass, JW; Cook, BA; Nomizu, S, 1992
)
0.49
" Analgesics administered intermittently were generally effective when given, however, the dosing interval was too long for the agents used resulting in frequent reports of poor pain relief."( Postoperative pain therapy: a survey of patients' expectations and their experiences.
McMillan, V; Owen, H; Rogowski, D, 1990
)
0.28
" All studied drugs proved to be safe at the administered dosage with regard to their influence on cerebral hemodynamics in very immature infants."( Cerebral hemodynamics in perinatal pharmacology.
Jorch, G; Rabe, H, 1991
)
0.28
" The A50 (dose producing 50% MPE) for each drug or drug combination was determined from the dose-response curve."( Antinociceptive interaction between opioids and medetomidine: systemic additivity and spinal synergy.
Bagley, J; Harris, S; Lin, BS; Lloyd, P; Messineo, E; Ossipov, MH, 1990
)
0.28
"Rectal thiopental is superior to this drug combination for pediatric sedation because it can be administered painlessly, has a more rapid onset and offset of action, and is of equal safety and efficacy at the dosage studied."( Rectal thiopental compared with intramuscular meperidine, promethazine, and chlorpromazine for pediatric sedation.
Carey, BE; Falk, JL; Malone, LC; O'Brien, JF, 1991
)
0.54
" To establish the safety and efficacy of an anesthetic regimen using intravenous meperidine and diazepam, all endoscopic procedures performed at one teaching institution in a 4-month period were retrospectively analyzed with regard to: (1) type and dosage of sedation/anesthesia, (2) endoscopic procedure involved, (3) effect of any underlying disease state, (4) side effects, (5) endoscopic complications, and (6) overall patient acceptance."( Evaluation of safe, effective intravenous sedation for utilization in endoscopic procedures.
Andrus, CH; Dean, PA; Ponsky, JL, 1990
)
0.51
" Patients number 8 through 16 gave higher ratings probably because a more idealized dosage regimen was being used by that time in the study."( Patient-controlled analgesia in patients with sickle cell vaso-occlusive crisis.
Castro, O; Finke, H; McPherson, E; Perlin, E; Pittman, J, 1990
)
0.28
" Dose-response curves of these components revealed that the photoactivatable aryl azido derivative has retained most of the inhibitory activity displayed by the parent substance."( Photoaffinity labelling of mitochondrial NADH: ubiquinone reductase with pethidine analogues.
Werner, S, 1989
)
0.28
" Dose-response curves were constructed for the opioid effects on C fibre evoked activity of dorsal horn nociceptive neurones following intrathecal application of each opioid, and the ED50 values were correlated with lipid solubility."( Intrathecal opioids, potency and lipophilicity.
Dickenson, AH; McQuay, HJ; Smallman, K; Sullivan, AF, 1989
)
0.28
" An accurate value for t1/2 beta may be particularly important in sequential dosing of analgesic medication."( Pharmacokinetics of meperidine in pregnancy.
Bucovaz, ET; Morrison, JC; Stafford, DT; Todd, EL, 1989
)
0.6
" Dosage requirements for anesthetic agents are shown."( Fentanyl-midazolam-flumazenil anesthesia for induced abortion.
Garamvölgyi, G; Hamar, O; Kálmán, A, 1989
)
0.28
" Again, the meperidine solution was repeated in the same dosage every 15 minutes as needed up to a total of three doses."( Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache.
Baggoley, CJ; Lane, PL; McLellan, BA, 1989
)
0.92
" Head injuries and a lower mean initial meperidine dosage were more prevalent in patients requiring repeat sedation (P less than ."( Intramuscular meperidine, promethazine, and chlorpromazine: analysis of use and complications in 487 pediatric emergency department patients.
Cantor, RM; Madden, CM; Terndrup, TE, 1989
)
0.91
" The main advantages were not only continuous pain relief despite the fact that the nonepidural control group required more than twice the dosage of morphine derivatives; also, the respiratory and pain-related recovery time was reduced."( [Catheter epidural analgesia in serial rib fractures].
Glatzl, A; Poigenfürst, J; Sandtner, W; Thonke, N, 1989
)
0.28
" Using the described intravenous dosing schedule, fentanyl was preferable to meperidine during labor because there was no prolonged maternal sedation or vomiting necessitating therapy and the requirement for neonatal naloxone was reduced."( Randomized comparison of meperidine and fentanyl during labor.
Parriott, JE; Rayburn, WF; Smith, CV; Woods, RE, 1989
)
0.81
" Dose-response curves revealed that the potency of these compounds is very comparable to that of the standard probe rotenone."( Pethidine analogues, a novel class of potent inhibitors of mitochondrial NADH: ubiquinone reductase.
Filser, M; Werner, S, 1988
)
0.27
" The patients were six days in hospital and were dosed two days with tablets, two days with mixture and finally another two days with tablets."( Analgesic effect and bioavailability of oral ketogan given as tablets or mixture to patients with chronic pain of malignant origin.
Kjaer, M; Nielsen, H, 1988
)
0.27
"A rabbit tooth pulp antinociceptive model was used to investigate the effect of prior administration of diazepam or muscimol on the potency and duration of fentanyl and meperidine Potency experiments compared ED(50) values in all-or-none dose-response assays between both muscimol (0."( Diazepam enhances fentanyl and diminishes meperidine antinociception.
Bergman, SA; Williams, G; Wyn, RL,
)
0.59
" Self-administered intramuscular analgesia could be instituted by a midwife with a dosage scheme similar to current practice."( Feasibility of self-administration analgesia by the intramuscular route in labour.
Li, DF; Rees, GA; Rosen, M, 1988
)
0.27
" The mean dosage of bupivacaine decreased from 21."( Comparison of continuous epidural infusion of a local anesthetic and administration of systemic narcotics in the management of pain after total knee replacement surgery.
Denson, DD; Edström, HH; Hartrick, CT; Hopson, CN; Knarr, DC; Pither, CE; Raj, PP; Vigdorth, E, 1987
)
0.27
" Patients given continuous infusions required more narcotic to control their pain and had more side effects than those treated with bolus injections alone, suggesting a dose-response relationship between narcotic dose and several known side effects."( Intravenous narcotic therapy for children with severe sickle cell pain crisis.
Buchanan, GR; Cole, TB; Smith, SJ; Sprinkle, RH, 1986
)
0.27
" Meperidine clearance was therefore evaluated in patients with traumatic injury and an effort was made to identify physiologic and/or clinical predictors of clearance which could facilitate initial dosage selection."( The pharmacokinetics of meperidine in acute trauma patients.
Edwards, DJ; Hassett, JM; Kirkwood, CF; Lalka, D; Lasezkay, G; Slaughter, RL, 1986
)
1.49
" After these dose-response curve determinations, chronic daily treatment with haloperidol (0."( Effects of drugs on schedule-controlled behavior in rats during chronic haloperidol administration.
McMillan, DE; Rastogi, SK, 1985
)
0.27
"1 ml/kg is recommended for cardiac catheterization, but no specific guidelines for dosing or frequency of monitoring have been established for patients undergoing other types of procedures."( Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients.
Clotz, MA; Krogg, EA; Nahata, MC, 1985
)
0.6
" 24 had received pentazocine after discharge; two required an increase in dosage and four expressed a preference for pentazocine."( Medicines evaluation and monitoring group: central nervous system effects of pentazocine.
Campbell, C; Davidson, JF; Gallon, SC; Henney, E; McAllion, S; Moir, DC; Wood, AJ, 1974
)
0.25
" The low oral bioavailability and rapid elimination of ketobemidone demonstrated in this study suggest that the usual dosage recommendation for oral Ketogin (ketobemidone 5--10 mg every 6--7 h) in patients with severe pain is too low."( Clinical pharmacokinetics and oral bioavailability of ketobemidone.
Anderson, P; Arnér, S; Bondesson, U; Boréus, LO; Hartvig, P, 1980
)
0.26
" Although the patient gave no previous history of narcotic use or abuse, he required morphine dosing rates as high as 56 mg/h to maintain adequate analgesia."( Extraordinary analgesic requirement in a patient previously unexposed to narcotics.
Batenhorst, RL; Baumann, TJ; Bennett, RL; Foster, TS; Graves, DA; Griffen, WO; Plumlee, JE,
)
0.13
"0 mg/kg) produced dose-related shifts to the right in the dose-response curves for the discriminative stimulus and rate-decreasing effects of morphine and ethylketazocine without affecting the response produced by meperidine."( Narcotic discrimination in pigeons: antagonism by naltrexone.
Herling, S; Solomon, RE; Valentino, RJ; Woods, JH, 1984
)
0.45
" With the dosage used in this experiment, there is no difference in the analgesic effect of tramadol and pethidine."( [Characterization of the effect of analgesics on the assessment of experimental pain in man. Pethidine and tramadol in a double-blind comparison].
Madler, C; Morawetz, RF; Parth, P, 1984
)
0.27
" The pooled mean dosage level of pentobarbital required for anesthesia was 12."( Meperidine-acepromazine-pentobarbital anesthesia in cats: reversal by 4-aminopyridine and yohimbine.
Booth, NH; Hatch, RC; Zahner, JM, 1984
)
1.71
" One subject who was administered dextroamphetamine did not produce a wave consistent with amphetamine with a dosage of 5 mg."( Qualitative measurement of drugs.
Gilbert, LM; Golz, A; Komorowski, FS; Westerman, ST, 1984
)
0.27
"A high-performance liquid chromatographic (HPLC) method for the quantitative determination of meperidine hydrochloride in pharmaceutical dosage forms was developed."( Quantitation of meperidine hydrochloride in pharmaceutical dosage forms by high-performance liquid chromatography.
Das Gupta, V, 1983
)
0.83
" When multiple oral or parenteral doses are required, dosing interval should be lengthened or repeated doses reduced below initial doses because of lower systemic clearance."( Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver.
Benowitz, NL; Jacob, P; Pond, SM; Tong, T, 1980
)
0.26
"01) during the first 2 h after dosage than the results after intramuscular administration."( A study of pethidine kinetics and analgesia in women in labour following intravenous, intramuscular and epidural administration.
Cummings, AJ; Davenport, HT; Husemeyer, RP; Rosankiewicz, JR, 1982
)
0.26
" Intravenous supplementation of the sedation was limited by the protocol to a maximum secobarbital dosage of 2 mg/kg."( The choice of sedation for computed tomography in children: a prospective evaluation.
Ashwal, S; Hasso, AN; Hinshaw, DB; Holden, BS; Schneider, S; Thompson, JR, 1982
)
0.26
"The changes in effects on motor activity of rats upon repeated (48 day) dosing with four narcotic analgesics were determined."( Motility response of rats to chronic constant-dose treatment with narcotics.
Davis, WM; Hemnani, KL; Pace, HB, 1982
)
0.26
" kg-1 of pethidine administered by subdural route realize a complete spinal anesthesia including motor, sensory and sympathetic blockade allowing surgical procedures in good conditions of security; --increasing the dosage of pethidine over 1 mg ."( [Subarachnoid anesthesia with pethidine].
Busu, G; Constantinescu, C; Daschievici, S; Ene, C; Jianu, E; Leoveanu, A; Mircea, N; Nedelcu, A, 1982
)
0.26
" The results suggest that in patients requiring repeated meperidine dosage the drug should be taken parenterally rather than orally to allow maximal analgesia and minimal formation of normeperidine."( Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects.
Benowitz, NL; Jacob, P; Pond, SM; Rigod, J; Tong, T, 1981
)
0.81
" Normeperidine blood concentration after intravenous dosing reached a maximum within 2 to 4 hr and remained at this value through 12 hr before modestly declining by 24 hr."( Meperidine disposition in man: influence of urinary pH and route of administration.
Branch, RA; Verbeeck, RK; Wilkinson, GR, 1981
)
2.26
" Pain control was poor during the first 4-h dosing interval."( Multiple intramuscular injections: a major source of variability in analgesic response to meperidine.
Austin, KL; Mather, LE; Stapleton, JV, 1980
)
0.48
" The aim of this study was to verify whether this action resulted from a local anaesthetic effect of pethidine or from inadequate fentanyl dosage in previous studies."( The effects of pethidine, fentanyl and lignocaine on postanaesthetic shivering.
Alfonsi, P; Chauvin, M; Hongnat, JM; Lebrault, C, 1995
)
0.29
" Morphine, pethidine and fentanyl, which showed a biphasic dose-response relationship with respect to seizure modulation, abolished the anticonvulsant activity of propofol to exhibit their own intrinsic activity in proconvulsant doses."( Interactions between opioid drugs and propofol in laboratory models of seizures.
Ahmad, I; Pleuvry, BJ, 1995
)
0.29
" However, the effect of differences in dosing protocol on tolerance to opioid analgesics of high or low efficacy has not been addressed."( The effect of intrinsic efficacy on opioid tolerance.
Duttaroy, A; Yoburn, BC, 1995
)
0.29
" At the end of treatment, the pumps and placebos were removed, and 4-24 h later, mice were tested in dose-response studies (tail flick) using the same drug that had been chronically administered."( The effect of intrinsic efficacy on opioid tolerance.
Duttaroy, A; Yoburn, BC, 1995
)
0.29
" The time to first administration of rescue analgesic, up to 24 h following dosing with the study medication, was recorded."( A comparison of intramuscular ketorolac and pethidine in the alleviation of renal colic.
Arkell, DG; Fletcher, MS; Iacovou, JW; Kaisary, AV; Philip, NH; Sandhu, DP, 1994
)
0.29
" Cisapride, at the dosage given, confers only modest benefit."( Small bowel motility following major intra-abdominal surgery: the effects of opiates and rectal cisapride.
Benson, MJ; Castillo, FD; Deeks, JJ; Roberts, JP; Rogers, J; Williams, NS; Wingate, DL, 1994
)
0.29
"Recommendations for the dosage of naloxone to reverse opiate depression in neonates were revised by the American Academy of Pediatrics in 1989."( [Administration of naloxone to newborn infants at obstetric departments in Norway].
Fagerli, I; Hansen, TW, 1994
)
0.29
" One alternative is the combination of glycopyrrolate, alfentanil and suxamethonium described here, although the ideal medication and dosage still remain to be defined."( Physiological changes, plasma beta-endorphin and cortisol responses to tracheal intubation in neonates.
Koivisto, M; Pokela, ML, 1994
)
0.29
"In order to evaluate the anticholinergic effect of fentanyl and pethidine, the influence of these drugs on the cumulative dose-response curves of carbacholine on the guinea-pig ileum has been investigated."( Fentanyl and pethidine are antagonists on muscarinic receptors in guinea-pig ileum.
Hustveit, O; Setekleiv, J, 1993
)
0.29
", owing to the higher dosage used in our study (50 mg as against 20 mg)."( [Oral premedication with clorazepate dipotassium. Comparison with oral premedication with flunitrazepam and intramuscular premedication with promethazine, pethidine and atropine in adults].
Gonzales, I; Kretz, FJ; Peidersky, P, 1993
)
0.29
" However, a greater number of patients receiving im injections required dosage adjustments than in the PCA group."( Comparison between patient-controlled analgesia and intramuscular meperidine after thoracotomy.
Boulanger, A; Bouré, B; Chartrand, D; Choinière, M; Choquette, R; Rousseau, P; Roy, D, 1993
)
0.52
"The analgesic and sedative effects of intravenous morphine or pethidine and their effect on anxiety were compared in a prospective, double-blind, randomised dose-response study."( Lack of analgesic effect of systemically administered morphine or pethidine on labour pain.
Ekblom, A; Ekman-Ordeberg, G; Hjelm, A; Irestedt, L; Olofsson, C, 1996
)
0.29
" This was done to evaluate the dose-response effect of these drugs when used for postoperative pain relief, and the results were applied to phase II of the study, in which all patients received ketamine pretreatment (total 30 mg) with each dose of lidocaine administered before and during surgery."( Ketamine potentiates analgesic effect of morphine in postoperative epidural pain control.
Ho, ST; Liaw, WJ; Su, YF; Tung, CS; Wong, CS,
)
0.13
" The resulting lowered dosage of epidural morphine needed for postoperative pain relief reduces, in turn, the incidence of side effects."( Ketamine potentiates analgesic effect of morphine in postoperative epidural pain control.
Ho, ST; Liaw, WJ; Su, YF; Tung, CS; Wong, CS,
)
0.13
" Therefore, the dosing of opioids to neonates should be titrated individually, and the patients should be observed carefully."( Overdoses of pethidine given to two preterm neonates.
Pokela, ML, 1997
)
0.3
" Patients with normal renal function rarely manifest seizure activity when given meperidine, but if the drug is used in large doses at frequent dosing intervals, seizures may occur."( Meperidine-induced generalized seizures with normal renal function.
Marinella, MA, 1997
)
1.97
" The dosing of the narcotic analgesics incorporates seldom-used, but well-published pharmacokinetics."( Oral narcotic protocol to reduce narcotic injections in refractory migraine patients.
Adelman, JU; Von Seggern, RL, 1997
)
0.3
" Further dosing with the particular analgesic was allowed if a cat was exhibiting unacceptable pain."( Comparison of carprofen and pethidine as postoperative analgesics in the cat.
Balmer, TV; Irvine, D; Jones, RS; Roberts, MJ; Slingsby, L; Taylor, PM; Waterman, AE; Waters, C, 1998
)
0.3
" Pethidine dosage by staff-controlled analgesia increased under study conditions, suggesting that mere pain-assessment and a 'competing' analgesic method motivated the BMT-unit staff to administer higher pethidine doses."( Patient-controlled versus staff-controlled analgesia with pethidine after allogeneic bone marrow transplantation.
Flesche, CW; Germing, U; Heyll, A; Schröter, S; Willers, R; Wolf, HH; Zucker, TP, 1998
)
0.3
"Patient-controlled sedation (PCS) enables titration of dosage to an individual's requirements and is potentially useful in colonoscopy."( Patient-controlled sedation and analgesia, using propofol and alfentanil, during colonoscopy: a prospective randomized controlled trial.
Criswell, J; Jones, C; Kimble, J; Patel, P; Roseveare, C; Seavell, C; Shepherd, H, 1998
)
0.3
" This prospective investigation involving postcesarean-section patients was undertaken to determine whether a combination of continuous infusion and demand dosing of meperidine would provide more effective analgesia than would demand dosing alone during the first 24 hours."( Combined continuous and demand narcotic dosing for patient-controlled analgesia after cesarean section.
Geranis, BJ; Rayburn, WF; Smith, CV; Woods, MP,
)
0.33
" Orderly dose-response functions suggested that our cumulative-dosing procedure is an efficient way of determining dose-response functions for multiple opioids within the same subjects within the same study."( Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers.
Walker, DJ; Zacny, JP, 1999
)
0.3
" Age, sex, weight, dosing interval, route of administration, duration of meperidine use, serum chemistry values, primary diagnosis, associated medical conditions, and medications concurrently being taken with meperidine were the parameters analyzed."( Meperidine utilization and compliance with Agency for Health Care Policy and Research guidelines in a tertiary care hospital.
Faut-Callahan, M; Paice, J; Pellegrini, JE, 1999
)
1.98
" In the dosage used, urapidil seems to be unable to prevent postanesthetic shivering."( A comparison of urapidil, clonidine, meperidine and placebo in preventing postanesthetic shivering.
Boldt, J; Maleck, WH; Piper, SN; Reich, DG; Schmidt, CC; Suttner, SW, 2000
)
0.58
" In the dosage used, we were unable to show a significant benefit of urapidil."( A comparison of urapidil, clonidine, meperidine and placebo in preventing postanesthetic shivering.
Boldt, J; Maleck, WH; Piper, SN; Reich, DG; Schmidt, CC; Suttner, SW, 2000
)
0.58
" We concluded that both tramadol and meperidine show a significantly faster response rate in the treatment of postepidural anesthetic shivering when compared with amitriptyline in the dosage used; tramadol had a decreased incidence of somnolence when compared with meperidine."( A comparison of tramadol, amitriptyline, and meperidine for postepidural anesthetic shivering in parturients.
Chu, KS; Tsai, YC, 2001
)
0.84
" However, due to the interindividual variability in plasma levels of ketobemidone, independent of phenotype, individual dosing based on the clinical response and therapeutic drug monitoring is recommended."( The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype.
Al-Shurbaji, A; Säwe, J, 2002
)
0.31
" This case report demonstrates the successful management of the patient with analgesia provided by a continuous spinal catheter dosed with a continuous infusion of fentanyl and supplemental meperidine."( Continuous spinal analgesia for labor and delivery in a parturient with hypertrophic obstructive cardiomyopathy.
Amano, K; Hoka, S; Kikuchi, S; Okamoto, H; Okutomi, T, 2002
)
0.5
"The combination of meperidine, atropine, and pentobarbital is a safe and effective premedication for cardiac catheterization when administered in standard dosage based upon body weight."( Oral meperidine, atropine, and pentobarbital for pediatric conscious sedation.
Porter, AG; Vincent, RN; Winn, CW,
)
0.97
"The dosage of thiopental was 50 mg per kg for infants under 6 months of age, 35 mg per kg between six and 12 months, and 25 mg per kg for older children."( Efficacy and safety of rectal thiopental, intramuscular cocktail and rectal midazolam for sedation in children undergoing neuroimaging.
Alp, H; Altinkaynak, S; Güler, I; Orbak, Z, 2002
)
0.31
" It is also safe and effective at the dosage studied in children undergoing MRI."( Efficacy and safety of rectal thiopental, intramuscular cocktail and rectal midazolam for sedation in children undergoing neuroimaging.
Alp, H; Altinkaynak, S; Güler, I; Orbak, Z, 2002
)
0.31
" The mean dosage and the total amount of Pethidine at 24 hours were significantly lower in G2 compared with G1."( Postoperative pain relief after laparoscopic cholecystectomy: a randomised prospective double-blind clinical trial.
Goroshina, J; Lepner, U; Samarütel, J, 2003
)
0.32
" Demerol in small dosage is safe and effective."( An evaluation of obstetrical analgesia.
FIST, HS, 1954
)
0.23
" Some differences in side-effects at equi-analgesic dosage were observed, particularly a reduction in histamine release."( Pharmacological actions of two new pethidine analogues.
LISTER, RE, 1960
)
0.24
" Information is provided comparing meperidine with other opioids, including dosage equivalency, pharmacodynamics, pharmacokinetics, cost, adverse effects, and drug interactions."( Removing meperidine from the health-system formulary--frequently asked questions.
Beckwith, MC; Chandramouli, J; Fox, ER, 2002
)
1.01
" Sedation dosage was standardized for each patient based on age, gender and weight from a previously published dosing nomogram."( The effect of moderate sedation on exocrine pancreas function in normal healthy subjects: a prospective, randomized, cross-over trial using the synthetic porcine secretin stimulated Endoscopic Pancreatic Function Test (ePFT).
Conwell, DL; Dumot, J; Fein, S; O'laughlin, C; Purich, E; Trolli, P; Vanlente, F; Vargo, J; Zuccaro, G, 2005
)
0.33
"Number of dosage units of parenteral analgesics issued to the ED from each hospital's pharmacy department was recorded monthly and aggregated in 3-month periods."( Pethidine in emergency departments: promoting evidence-based prescribing.
Davis, SR; Day, RO; Graudins, A; Graudins, LV; Kaye, KI; Rotem, T; Welch, SA, 2005
)
0.33
" As yet, standardized dosing regimens for individual patients do not exist."( Endoscopist administered sedation during ERCP: impact of chronic narcotic/benzodiazepine use and predictive risk of reversal agent utilization.
Baron, TH; Gleeson, FC; Papachristou, DJ; Papachristou, GI; Petersen, BT, 2007
)
0.34
"Group M: mean dosage of pethidine and midazolam 88."( Midazolam and pethidine versus propofol and fentanyl patient controlled sedation/analgesia for upper gastrointestinal tract ultrasound endoscopy: a prospective randomized controlled trial.
Agostoni, M; Arcidiacono, PG; Fanti, L; Gemma, M; Strini, G; Testoni, PA; Torri, G, 2007
)
0.34
" Demerol requires a higher dosage than methadone, but produces less respiratory depression."( A comparison of certain actions of demerol and methadone.
BUCHANAN, OH; TAINTER, ML, 1949
)
0.23
" Further studies should address the optimization of dosing and lock out setting."( Remifentanil vs. meperidine for patient-controlled analgesia during colonoscopy: a randomized double-blind trial.
Agostoni, M; Alberto, TP; Antonio, F; Facciorusso, A; Fanti, L; Gambino, G; Gemma, M; Giorgio, T; Giulia, G; Guslandi, M; Marco, G; Mario, G; Massimo, A; Testoni, PA; Torri, G, 2009
)
0.69
" Rats (n=14) were dosed with 0 (n=2) or 30 mg/kg (n=12) meperidine (i."( Examination of the effect of dose-death interval on detection of meperidine exposure in decomposed skeletal tissues using microwave-assisted extraction.
Desrosiers, NA; Watterson, JH, 2011
)
0.85
" Trials were grouped into placebo-controlled, dosage and head-to-head comparisons."( Sedation of children undergoing dental treatment.
Ashley, PF; Furness, S; Lourenço-Matharu, L, 2012
)
0.38
" The usage of conscious sedation, dosage of lidocaine/pethidin was similar between groups."( Comparison of a powered bone marrow biopsy device with a manual system: results of a prospective randomised controlled trial.
Bucher, CM; Dirnhofer, S; Lehmann, T; Passweg, J; Rovó, A; Tichelli, A; Tzankov, A, 2013
)
0.39
" Post-operative pethidine dosage was significantly lower in the 2ILC group (0."( From multi-incision to single-incision laparoscopic cholecystectomy step-by-step: one surgeon's self-taught experience and retrospective analysis.
Chuang, SH, 2013
)
0.39
" Based on dosage equivalency conversion, equal doses of fentanyl and meperidine were used."( Impact of fentanyl in lieu of meperidine on endoscopy unit efficiency: a prospective comparative study in patients undergoing EGD.
Crowell, MD; Dzeletovic, I; Gurudu, SR; Harris, LA; Harrison, ME; Heigh, RI; Leighton, JA; Pasha, SF; Ramirez, FC; Yows, CR, 2013
)
0.91
" Increasing the dosage of spinal morphine does not decrease postoperative meperidine consumption, but may lead to respiratory depression in rare cases."( Low-dose spinal morphine for post-thoracotomy pain: a prospective randomized study.
Lertpaitoonpan, W; Phanchaipetch, T; Pongpayuha, P; Sanansilp, V; Suksompong, S; von Bormann, B, 2013
)
0.62
" Dosage of analgesic medication consumption was retrieved from patients' charts."( Combined spinal and general anesthesia vs general anesthesia for robotic sacrocervicopexy: a randomized controlled trial.
Awad, N; Lowenstein, L; Mustafa, S; Nasir, H; Segal, D, 2014
)
0.4
"A hot-plate test was used to evaluate the analgesic effect after pethidine (20 mg/kg) or saline injection at different dosing times."( Chronopharmacodynamics and chronopharmacokinetics of pethidine in mice.
Li, X; Liu, D; Xu, Y; Yu, Z; Zhang, C, 2014
)
0.4
"These results suggest that the pharmacodynamics and pharmacokinetics of pethidine in mice vary significantly according to the dosing time, which implies that the time of administration should be considered in the rational clinical use of pethidine to maximise analgesia and minimise the adverse effects."( Chronopharmacodynamics and chronopharmacokinetics of pethidine in mice.
Li, X; Liu, D; Xu, Y; Yu, Z; Zhang, C, 2014
)
0.4
" Increased dosing might result in a ceiling effect, and thus less analgesia than expected."( Nalbuphine for postoperative pain treatment in children.
Pogatzki-Zahn, E; Reichl, SU; Schnabel, A; Zahn, PK, 2014
)
0.4
" Except for benzodiazepines, which were dosed higher in women than men, equal doses of sedation were given to female and male patients."( Practice patterns of sedation for colonoscopy.
Childers, RE; Sonnenberg, A; Williams, JL, 2015
)
0.42
" The objective of this study was to determine the level of meperidine use in older adults and assess the dosage and duration of meperidine with reference to these safety recommendations."( The safety of meperidine prescribing in older adults: A longitudinal population-based study.
Bugden, S; Falk, J; Friesen, KJ, 2016
)
1.04
" Studies were grouped into placebo-controlled, dosage and head-to-head comparisons."( Sedation of children undergoing dental treatment.
Ashley, PF; Chaudhary, M; Lourenço-Matharu, L, 2018
)
0.48
"This retrospective study compares the efficacy and safety of variable dosing of Midazolam (Mid) with and without Meperidine (Mep) combinations for managing varying levels of anxiety and uncooperative behavior of young pediatric dental patients over a thirty-five-year period."( Retrospective Comparisons of the Efficacy and Safety of Variable dosing of Midazolam with and without Meperidine for Management of Varying Levels of Anxiety of Pediatric Dental Patients: 35 years of Sedation Experience.
Nathan, JE, 2022
)
1.15
"Reviews of the sedation logs of 1,785 sedation visits are compared with emphasis on what dosing proves both safe and effective for differing levels of challenging pediatric behavior."( Retrospective Comparisons of the Efficacy and Safety of Variable dosing of Midazolam with and without Meperidine for Management of Varying Levels of Anxiety of Pediatric Dental Patients: 35 years of Sedation Experience.
Nathan, JE, 2022
)
0.94
"This retrospective study compares the efficacy and safety of variable dosing of Chloral Hydrate - Hydroxyzine with and without Meperidine (Mep)for managing varying levels of anxiety and uncooperative behavior of young pediatric dental patients over a 35-year period."( Comparisons of Varying Dosages of Chloral Hydrate-Hydroxyzine with and without Meperidine for Managing Challenging Pediatric Dental Behavior: A Retrospective study of 35 years of Sedation Experiences.
Nathan, JE, 2022
)
1.15
"Reviews of the sedation logs of 2,610 children, 3-7 years were compared in search of what dosing proves safe and effective for differing levels of challenging behavior."( Comparisons of Varying Dosages of Chloral Hydrate-Hydroxyzine with and without Meperidine for Managing Challenging Pediatric Dental Behavior: A Retrospective study of 35 years of Sedation Experiences.
Nathan, JE, 2022
)
0.95
"Where Mep was used, success rates were consistently higher; need for higher-end dosing of CH was not found beneficial when Mep was included."( Comparisons of Varying Dosages of Chloral Hydrate-Hydroxyzine with and without Meperidine for Managing Challenging Pediatric Dental Behavior: A Retrospective study of 35 years of Sedation Experiences.
Nathan, JE, 2022
)
0.95
"There appears to be strong basis for the safety and efficacy of the use of CH-H-Mep in combination at lower dosing than historically used."( Comparisons of Varying Dosages of Chloral Hydrate-Hydroxyzine with and without Meperidine for Managing Challenging Pediatric Dental Behavior: A Retrospective study of 35 years of Sedation Experiences.
Nathan, JE, 2022
)
0.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
opioid analgesicA narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.
kappa-opioid receptor agonistA compound that exhibits agonist activity at the kappa-opioid receptor.
mu-opioid receptor agonistA compound that exhibits agonist activity at the mu-opioid receptor.
antispasmodic drugA drug that suppresses spasms. These are usually caused by smooth muscle contraction, especially in tubular organs. The effect is to prevent spasms of the stomach, intestine or urinary bladder.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
piperidinecarboxylate ester
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)22.25000.21005.553710.0000AID1526751
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)Ki17.80000.00030.37088.1600AID65195
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)Ki0.41200.00000.705610.0000AID204538
Delta-type opioid receptorMus musculus (house mouse)IC50 (µMol)20.25000.00010.729810.0000AID145928; AID150235
Kappa-type opioid receptorMus musculus (house mouse)IC50 (µMol)20.25000.00131.538010.0000AID145928; AID150235
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)13.60500.00010.813310.0000AID150234; AID150235; AID152239
Delta-type opioid receptorHomo sapiens (human)IC50 (µMol)16.83330.00020.75218.0140AID148078; AID150234; AID150235
Kappa-type opioid receptorHomo sapiens (human)IC50 (µMol)14.29000.00001.201110.0000AID147859; AID150234; AID150235
Mu-type opioid receptorMus musculus (house mouse)IC50 (µMol)20.25000.00081.699210.0000AID145928; AID150235
Mu-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.50000.00020.660310.0000AID150234
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)50.10410.00091.901410.0000AID243151; AID392051; AID576612
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)EC50 (µMol)9.40000.00000.32639.4000AID392933
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (118)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
cholesterol biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
response to toxic substanceLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxLiver carboxylesterase 1Homo sapiens (human)
negative regulation of cholesterol storageLiver carboxylesterase 1Homo sapiens (human)
epithelial cell differentiationLiver carboxylesterase 1Homo sapiens (human)
cholesterol homeostasisLiver carboxylesterase 1Homo sapiens (human)
reverse cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
medium-chain fatty acid metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cellular response to cholesterolLiver carboxylesterase 1Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulusLiver carboxylesterase 1Homo sapiens (human)
cholesterol ester hydrolysis involved in cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid secretionLiver carboxylesterase 1Homo sapiens (human)
lipid catabolic processLiver carboxylesterase 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (44)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
sterol esterase activityLiver carboxylesterase 1Homo sapiens (human)
methylumbelliferyl-acetate deacetylase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylesterase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylic ester hydrolase activityLiver carboxylesterase 1Homo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
cytoplasmLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulum lumenLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
cytosolLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
plasma membraneKappa-type opioid receptorMus musculus (house mouse)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorMus musculus (house mouse)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (110)

Assay IDTitleYearJournalArticle
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1134072Analgesic activity in dog assessed as rippling of skin at 5 mg/kg, ip after 2 hrs by radiant heat assay1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Analgesic and tranquilizing activity of 5,8-disubstituted 1-tetralone Mannich bases.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1149030Analgesic activity in sc dosed white mouse by hot plate method1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Synthesis and pharmacology of 2,9alpha-dimethyl-2'-hydroxy-6,7-benzomorphan.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID150236Ratio of IC50 values for incubations in the presence of 100 mM NaCl to those incubations in its absence1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Synthesis and biological activity of fluoroalkylamine derivatives of narcotic analgesics.
AID1146574Narcotic analgesic activity in sc dosed rat assessed as inhibition of phenazocine-induced effect by D'Amour-Smith tail flick test1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
(2-exo-3-endo)-2-Aryltropane-3-carboxylic esters, a new class of narcotic antagonists.
AID1123082Displacement of radiolabeled dihydromorphine from opioid receptor in rat brain homogenates1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
N-(2-Cyanoethyl) derivatives of meperidine, ketobemidone, and a potent 6,7-benzomorphan.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1526751Inhibition of human OCT1 expressed in HEK293 cells assessed as reduction in ASP+ substrate uptake by microplate reader based analysis2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1134076Analgesic activity in mouse assessed as tail-flick latency period at 100 mg/kg, ip after 2 hrs by by tail flick test1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Analgesic and tranquilizing activity of 5,8-disubstituted 1-tetralone Mannich bases.
AID1526733Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake at 0.5 uM incubated for 2 mins by LC-MS/MS analysis relative to control empty vector transfected cells2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1146575Narcotic analgesic activity in po dosed rat assessed as inhibition of phenazocine-induced effect by D'Amour-Smith tail flick test1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
(2-exo-3-endo)-2-Aryltropane-3-carboxylic esters, a new class of narcotic antagonists.
AID392051Inhibition of human ERG channel in HEK293 cells by voltage-clamp method2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29813Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID149046The ratio between [3H]naloxone binding in the presence and absence of 100 mM NaCl1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
N-substituent modulation of opiate agonist/antagonist activity in resolved 3-methyl-3-(m-hydroxyphenyl)piperidines.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID114683Effective dose for antinociceptive activity in mice hot plate test s.c.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Racemic and optically active 1,3,3-trimethyl-4-phenyl-4-(propionyloxy)piperidine.
AID150234Inhibition of Opioid receptors with [3H]naloxone binding in the absence of NaCl1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Synthesis and biological activity of fluoroalkylamine derivatives of narcotic analgesics.
AID1134073Analgesic activity in mouse at 100 mg/kg, ip after 2 hrs by hot plate assay1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Analgesic and tranquilizing activity of 5,8-disubstituted 1-tetralone Mannich bases.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1134065Neuroleptic activity in ip dosed rat assessed as drug required for blocking discriminated jump-out avoidance behavior in after 1 hr1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Analgesic and tranquilizing activity of 5,8-disubstituted 1-tetralone Mannich bases.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID178594Effective dose for antinociceptive activity in rat tail-withdrawal test i.v.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Racemic and optically active 1,3,3-trimethyl-4-phenyl-4-(propionyloxy)piperidine.
AID1146144Displacement of [3H]dihydromorphine from opioid receptor in rat brain homogenate1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Heterocyclic and piperonylic acid esters of 1-methyl-4-piperidinol as analgesics.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID149034Inhibition of [3H]naloxone receptor binding to opioid receptor in the absence of NaCl1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
N-substituent modulation of opiate agonist/antagonist activity in resolved 3-methyl-3-(m-hydroxyphenyl)piperidines.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID149035Inhibition of [3H]naloxone receptor binding to opioid receptor in the presence of 100 mM NaCl1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
N-substituent modulation of opiate agonist/antagonist activity in resolved 3-methyl-3-(m-hydroxyphenyl)piperidines.
AID185210Morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR), administered by intravenous.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID145928Tested for displacement of radioligand [3H]-Naloxone from opiate receptor1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Structure-affinity relationship studies on 5-HT1A receptor ligands. 1. Heterobicyclic phenylpiperazines with N4-alkyl substituents.
AID125754Antagonistic activity to show narcotic effect induced by subcutaneous administration of 21.08 umol/Kg of morphine in mouse tail-flick test; NA=No antagonism1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Effects of addition of a 2-methyl group to ethyl nipecotates (beta-meperidines) on receptor affinities and opiate agonist/antagonist activities.
AID1526752Passive membrane permeability by LC-MS/MS analysis based PAMPA2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID416493Analgesic activity in albino mouse assessed as response latency time to pain stimulus at 5 mg/kg, ip after 3 hrs by hot plate method2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, analgesic, anti-inflammatory and antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing thiazolotriazoles.
AID456232Activity at human recombinant CES1 expressed in baculovirus-infected Spodoptera frugiperda Sf21 cells assessed as substrate hydrolysis by fluorescence assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
In silico prediction of human carboxylesterase-1 (hCES1) metabolism combining docking analyses and MD simulations.
AID65195Displacement of [3H]WIN-35428 from dopamine transporter (DAT)1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Synthesis, dopamine and serotonin transporter binding affinities of novel analogues of meperidine.
AID174638Duration to produce analgesic activity was measured in rats by tail withdrawal reflex test (TWR), intravenous administration.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID147859Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands.
AID141504Binding affinity against mu opioid receptor was determined in brain membrane preparations from male Hartley guinea-pigs1998Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14
C-alkylated spiro[benzofuran-3(2H),4'-1'-methyl-piperidine-7-ols] as potent opioids: a conformation-activity study.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1132336Analgesic activity in dog assessed as increase in response threshold at 16 mg/kg, sc measured 0.5 to 2 hrs post treatment by radiant heat method relative to control1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Analgesic and tranquilizing activity of 5,8-disubstituted 2-aminomethyl-3,4-dihydronaphthalenes.
AID1123083Analgesic activity in sc dosed mouse by hot plate assay1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
N-(2-Cyanoethyl) derivatives of meperidine, ketobemidone, and a potent 6,7-benzomorphan.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID136959Relative Analgesic activity of compound to the N-methyl homologue assayed by the mouse hotplate method1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Quantitative structure-activity relationships of aromatic esters of 1-methyl-4-piperidinol as analgesics.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID152239Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID235172Relative affinity for dopamine and serotonin transporters1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Synthesis, dopamine and serotonin transporter binding affinities of novel analogues of meperidine.
AID1132329Analgesic activity in Swiss CD mouse assessed as elevation of response latency at 56 mg/kg, ip measured 0.5 hr post treatment by tail flick method relative to control1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Analgesic and tranquilizing activity of 5,8-disubstituted 2-aminomethyl-3,4-dihydronaphthalenes.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID392933Agonist activity at human cloned mu opioid receptor by [35S]GTPgammaS binding assay2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Discovery of mu-opioid selective ligands derived from 1-aminotetralin scaffolds made via metal-catalyzed ring-opening reactions.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1132319Analgesic activity in Swiss CD mouse at 56 mg/kg, ip measured 0.5 hr post treatment by hot-plate method relative to control1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Analgesic and tranquilizing activity of 5,8-disubstituted 2-aminomethyl-3,4-dihydronaphthalenes.
AID148078Binding affinity against delta-opiate receptor (human) using [3H]-DPDPE radioligand2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID149142Binding affinity against Opioid receptor kappa 1 was determined in brain membrane preparations from male Hartley guinea-pigs1998Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14
C-alkylated spiro[benzofuran-3(2H),4'-1'-methyl-piperidine-7-ols] as potent opioids: a conformation-activity study.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1132320Analgesic activity in Swiss CD mouse at 56 mg/kg, ip measured 2 hrs post treatment by hot-plate method relative to control1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Analgesic and tranquilizing activity of 5,8-disubstituted 2-aminomethyl-3,4-dihydronaphthalenes.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID150235Inhibition of Opioid receptors binding by inhibiting specific [3H]naloxone binding by 50% in the presence of 100 mM NaCl1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Synthesis and biological activity of fluoroalkylamine derivatives of narcotic analgesics.
AID1134066Analgesic activity in rat assessed as median foot shock required to elicit flinch-jump at 32 mg/kg, ip after 2 hrs1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Analgesic and tranquilizing activity of 5,8-disubstituted 1-tetralone Mannich bases.
AID204538Displacement of [3H]paroxetine from serotonin transporter (SERT)1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Synthesis, dopamine and serotonin transporter binding affinities of novel analogues of meperidine.
AID392934Intrinsic activity at human cloned mu opioid receptor at 100 uM by [35S]GTPgammaS binding assay relative to DAMGO2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Discovery of mu-opioid selective ligands derived from 1-aminotetralin scaffolds made via metal-catalyzed ring-opening reactions.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID416491Analgesic activity in albino mouse assessed as response latency time to pain stimulus at 5 mg/kg, ip after 1 hr by hot plate method2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, analgesic, anti-inflammatory and antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing thiazolotriazoles.
AID114834Effective dose required for analgesic potency in the hotplate procedure after sc injection into mice.1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Stereochemical studies on medicinal agents. 25. Absolute configuration and analgetic potency of beta-1,2-dimethyl-2-phenyl-4-(propionyloxy)piperidine enantiomers.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1526732Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake at 0.1 uM incubated for 2 mins by LC-MS/MS analysis relative to control empty vector transfected cells2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1132330Analgesic activity in Swiss CD mouse assessed as elevation of response latency at 56 mg/kg, ip measured 2 hrs post treatment by tail flick method relative to control1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Analgesic and tranquilizing activity of 5,8-disubstituted 2-aminomethyl-3,4-dihydronaphthalenes.
AID131898Effective dose to show narcotic analgesic activity was evaluated in mouse tail-flick test when administered subcutaneously1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Effects of addition of a 2-methyl group to ethyl nipecotates (beta-meperidines) on receptor affinities and opiate agonist/antagonist activities.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1526731Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake at 0.05 uM incubated for 2 mins by LC-MS/MS analysis relative to control empty vector transfected cells2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1346329Human kappa receptor (Opioid receptors)2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands.
AID1346361Human delta receptor (Opioid receptors)2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands.
AID1346364Human mu receptor (Opioid receptors)2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,135)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903346 (65.16)18.7374
1990's818 (15.93)18.2507
2000's581 (11.31)29.6817
2010's323 (6.29)24.3611
2020's67 (1.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 91.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index91.09 (24.57)
Research Supply Index8.85 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index170.19 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (91.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1,228 (21.36%)5.53%
Reviews194 (3.38%)6.00%
Case Studies322 (5.60%)4.05%
Observational11 (0.19%)0.25%
Other3,993 (69.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (65)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Intrathecal Injection of Pethidine and Dexamethasone Versus Intrathecal Injection of Bupivacaine in Lower Extremity Orthopedic Surgeries: Comparative Study [NCT05303311]Phase 2/Phase 346 participants (Actual)Interventional2021-01-15Active, not recruiting
Comparison Between Meperidine and Drotaverine Regarding the Effect on the Duration of the First Stage of Labor in Full Term Primigravidae [NCT01236651]Phase 2200 participants (Anticipated)Interventional2010-11-30Not yet recruiting
Comparison of Dexmedetomidine and Meperidine for the Prevention of Shivering Following Coronary Artery Bypass Graft: Study Protocol of a Randomized Controlled Trial [NCT04735965]Phase 4180 participants (Anticipated)Interventional2021-07-15Recruiting
Subrectal and Subcutaneous Wound Infiltration With Bupivacaine Versus Pethidine for Postcesarean Section Pain Relief: a Randomized Clinical Trial [NCT03652116]Phase 2/Phase 378 participants (Actual)Interventional2017-04-21Completed
Caudal Extradural Catheterization in Pediatric Renal Transplant: Effect on Perioperative Hemodynamics and Pain Scoring. [NCT02037802]60 participants (Actual)Interventional2014-03-31Completed
The Effect of Pethidine Analgesia on Labor Duration and Maternal-Fetal Outcomes [NCT03882814]240 participants (Actual)Observational2017-07-01Completed
A Randomized Comparison of Midazolam With Meperidine and Dexmedetomidine Versus Midazolam With Meperidine and Propofol for Sedation During ERCP [NCT02475824]Phase 4258 participants (Actual)Interventional2015-05-31Completed
Analysis of Contemporary Labor Patterns Measured Via Transperineal Ultrasonography [NCT02393144]1,000 participants (Anticipated)Interventional2015-02-28Recruiting
Pethidine Versus Nitrous Oxide for Pain Relief During Labor Among Multiparous. A Randomized Controlled Trial [NCT02783508]214 participants (Actual)Interventional2016-08-31Completed
A Randomised Controlled Trial of Remifentanil Intravenous Patient Controlled Analgesia (PCA) Versus Intramuscular Pethidine for Pain Relief in Labour [NCT02179294]Phase 4401 participants (Actual)Interventional2014-05-31Completed
Phase II Study of Comparison of Two Sedation Regimen for Transesophageal Echocardiography in Point of View of Blood Pressure Response, Safety and Patient Comfort [NCT01567657]Phase 2200 participants (Actual)Interventional2012-01-31Completed
Efficacy of Intravenous Hyoscine ButylBromide as an Analgesic During the First Stage of Labor: A Randomized Controlled Trial [NCT02557087]Phase 2104 participants (Anticipated)Interventional2015-09-30Not yet recruiting
Meperidine as the Single Sedative Agent for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy. [NCT01948921]110 participants (Actual)Interventional2013-09-30Completed
Assessment of Subarachnoid Anesthesia With Low Dose of Pethidine and Combination of Ropivacaine With Fentanyl for Urologic Surgical Operations. [NCT03260283]Phase 2/Phase 3104 participants (Actual)Interventional2017-08-16Completed
Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering Following Subarachnoid Block [NCT02441673]Phase 2130 participants (Anticipated)Interventional2018-10-12Not yet recruiting
Oblique Subcostal Transverses Abdominal Plane Block in Laparoscopic Cholecystectomy [NCT02707250]Phase 2/Phase 3120 participants (Anticipated)Interventional2015-03-31Recruiting
Ketamine-propofol Versus Pethidine-propofol for Sedating Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) [NCT02651792]Phase 250 participants (Actual)Interventional2015-01-31Completed
[NCT00848861]92 participants (Actual)Interventional2006-02-28Completed
Dexmedetomidine Versus Ketamine to Prevent Shivering Associated With Intrathecal Anesthesia in Patients Undergoing Knee Arthroscopy:A Randomized, Controlled Double Blinded Study. [NCT06082076]Phase 2/Phase 390 participants (Anticipated)Interventional2023-11-30Not yet recruiting
Comparing Pediatric Oral Sedation Outcomes Using Midazolam and Hydroxyzine With and Without Meperidine [NCT04068948]Phase 437 participants (Actual)Interventional2019-06-25Completed
Ultrasound Guided Erector Spinae Block Versus Thoracic Paravertebral Block for Postoperative Pain Control After Open Nephrectomy : A Randomized Controlled Trial [NCT04719507]45 participants (Anticipated)Interventional2021-01-31Not yet recruiting
Efficacy of Intravenous Paracetamol as an Analgesic During the First Stage of Labor: A Randomized Controlled Trial [NCT02578251]Phase 2104 participants (Anticipated)Interventional2015-10-31Not yet recruiting
Analgesic Effects of Intravenous Acetaminophen on Labor Pain [NCT01394731]Phase 40 participants Interventional2010-12-31Completed
Ultrasound Guided Erector Spinae Plane Block Versus Quadratus Lumborum Block in Pediatric Open Renal Surgeries: A Randomized Comparative Study. [NCT05386121]Phase 460 participants (Anticipated)Interventional2022-05-20Not yet recruiting
Propofol Patient-controlled Sedation Versus Target-controlled Infusion in Outpatient Colonoscopy [NCT04686058]Phase 3105 participants (Actual)Interventional2014-03-31Completed
Ultrasound Guided Erector Spinae Plane Block in Scoliotic Adolescents Undergoing Posterior Spine Instrumentation . A Randomized Controlled Trial [NCT03968146]Phase 230 participants (Actual)Interventional2019-06-18Completed
Ultrasound Guided Transversus Abdominis Plane Block (TAPB) vs Surgical TAPB With Bupivacaine for Acute Pain Control in Cesarean Section: A Randomized Clinical Trial [NCT05750992]50 participants (Anticipated)Interventional2023-04-10Recruiting
Nurse-Administered Propofol Sedation by PCA Pump Versus Diazemuls / Pethidine in Outpatient Colonoscopy: A Randomized Controlled Study [NCT00566683]194 participants (Actual)Interventional2005-07-31Completed
[NCT02016976]40 participants (Anticipated)Interventional2014-01-31Not yet recruiting
[NCT02039453]160 participants (Anticipated)Interventional2013-09-30Recruiting
Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial [NCT00596414]Phase 4180 participants (Actual)Interventional2003-05-31Completed
Efficacy of Intravenous Tenoxicam as an Analgesic During the First Stage of Labor: A Randomized Controlled Trial [NCT02549118]Phase 2100 participants (Anticipated)Interventional2015-09-30Not yet recruiting
Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial [NCT02867800]Phase 124 participants (Actual)Interventional2016-07-31Active, not recruiting
Intrathecal Dexamethasone in Patients Undergoing Transuretheral Prostatectomy. [NCT02619019]Phase 290 participants (Actual)Interventional2015-11-30Completed
Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy, a Double-blind, Randomized Controlled Study [NCT01547520]140 participants (Actual)Interventional2011-06-30Completed
Unilateral Dual Transversus Abdominis Plane Block in Pediatric Renal Transplant: A Randomized Control Study [NCT02858622]44 participants (Actual)Interventional2016-12-31Completed
Optimal Timing of Endoscopic Intervention After Extracorporeal Shock-Wave Lithotripsy in the Treatment of Chronic Pancreatitis With Pancreatic Stones. [NCT05270434]225 participants (Anticipated)Interventional2022-03-01Not yet recruiting
Neuraxial Pethidine After Lumbar Surgery Trial [NCT00163553]Phase 360 participants (Anticipated)Interventional2004-12-31Recruiting
Comparison of Intrathecal Levobupivacaine Combined With Sufentanil, Fentanyl, or Placebo for Elective Caesarean Section: A Prospective, Randomized, Double-blind, Controlled Study [NCT01858090]Phase 393 participants (Actual)Interventional2009-01-31Completed
Traitement Des Frissons Lors de la césarienne Sous anesthésie péridurale Durant le Travail - un Essai Clinique randomisé Comparant la dexmédétomidine et la mépéridine [NCT03115047]Phase 380 participants (Actual)Interventional2017-05-07Completed
EuroHYP-1: European Multicentre, Randomised, Phase III Clinical Trial of Therapeutic Hypothermia Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischaemic Stroke [NCT01833312]Phase 398 participants (Actual)Interventional2013-07-31Terminated(stopped due to Slow recruitment, cessation of funding)
A Prospective, Non-inferiority Randomized Double-blinded Trial Comparing Fentanyl and Midazolam vs Diazepam and Pethidine for Pain Relief During Oocyte Retrieval [NCT02494180]Phase 4170 participants (Actual)Interventional2016-03-31Completed
Evaluation of Ultrasound-Guided Erector Spinae Plane Block for Postoperative Analgesia in Adult Patients Undergoing Major Abdominal Surgery: A Prospective Randomized Controlled Clinical Trial [NCT04382209]56 participants (Actual)Interventional2020-06-01Active, not recruiting
The Effect of Different Sedation Regimes Administered by Anesthesiologists or Endoscopists on Cognitive Functions in Lower Gastrointestinal System Endoscopy [NCT02486328]Phase 4103 participants (Actual)Interventional2015-05-31Completed
Epidural Analgesia Versus IV Meperidine for Labor Pain Control. Objective Evaluation of the Pain Intensity Influence on the Autonomic Nervous System. [NCT00296751]60 participants (Anticipated)Interventional2006-03-31Completed
Combination Use of Intravenous Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography ; A Randomized Control Trial [NCT06111872]Phase 290 participants (Anticipated)Interventional2023-07-18Recruiting
Effects of Different Local Anesthetic Concentrations With Epidural Tap Method for Labor Analgesia [NCT05499234]Phase 170 participants (Anticipated)Interventional2022-08-01Recruiting
Comparison Between Two Different Dosages of Remifentanil Administered by PCSA (Patient Controlled Sedation and Analgesia) and Meperidine During Colonoscopy: A Randomized Double-Blind Trial [NCT01229527]Phase 490 participants (Actual)Interventional2009-04-30Completed
A Comparison of Meperidine for Post-Cesarean Analgesia: Bolus Versus Infusion and Bolus [NCT01741259]273 participants (Actual)Interventional2013-08-31Completed
The Effect of Intraoperative Tramadol on Postoperative Opioid Requirements After Laparoscopic Sleeve Gastrectomy for Morbid Obese Patients (A Retrospective Multicentric Cohort Study) [NCT05696886]400 participants (Actual)Interventional2021-01-01Completed
Intraoperative Use of Dexketoprofen Trometamol, Tramadol Hcl, Pethidine Hcl and Their Combinations for Postoperative Pain Management in Laparoscopic Nissen Fundoplication [NCT01558622]Phase 472 participants (Anticipated)Interventional2012-03-31Active, not recruiting
Comparative Study Between the Prophylactic Intravenous Administrations of Acetaminophen vs Dexamethasone vs Pethidine Regarding the Incidence of Shivering Induced by Single Shot Spinal Anesthesia in the Orthopedic Surgeries of the Lower Limbs [NCT05284409]Phase 4108 participants (Anticipated)Interventional2022-07-01Active, not recruiting
Efficacy and Safety of Intravenous Paracetamol in Manament of Labour Pain in a Low Resource Setting [NCT04744727]96 participants (Actual)Interventional2019-03-01Completed
[NCT02493192]Phase 4110 participants (Anticipated)Interventional2015-07-31Not yet recruiting
Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis [NCT02625181]27,034 participants (Actual)Interventional2016-07-31Completed
Comparison of Meperidine and Fentanyl on Pain Scale and Quality of Life in Cervical Cancer Patients Receiving Brachytherapy: A Double-blind, Randomized Controlled Trial [NCT02684942]Phase 440 participants (Actual)Interventional2012-10-31Completed
Safety and Efficacy of Dexmedetomidine in Treating Post Spinal Anesthesia Shivering: A Clinically Controlled Dose-finding Study. [NCT02382432]Phase 2120 participants (Actual)Interventional2013-12-31Completed
The Comparison of Intravenous Magnesium Sulphate and Intravenous Meperidine for Prevention of Shivering During Spinal Anesthesia [NCT05110469]Phase 4100 participants (Actual)Interventional2021-02-01Completed
Remifentanil Only vs. Combination Group Midazolam + Meperidine During Elective Colonoscopy [NCT01693185]Phase 460 participants (Actual)Interventional2012-12-31Completed
Is There Any Effect of Meperidine on the Length of Duration of Labor? A Prospective Randomized Controlled Trial. [NCT01555671]Phase 4250 participants (Actual)Interventional2012-01-01Completed
Efficacy of Pethidine, Ketorolac And Xylocaine Gel As Analgesics For Pain Control In Shockwave Lithotripsy Single Blinded Randomized Controlled Trial [NCT03032458]Phase 4165 participants (Actual)Interventional2017-01-31Completed
Efficacy and Safety Profiles of Sedation With Propofol Combined With Intravenous Midazolam and Meperidine Versus Intravenous Midazolam and Meperidine for Ambulatory Endoscopic Retrograde-cholangiopancreatography(ERCP). [NCT01709422]Phase 4140 participants (Actual)Interventional2010-06-30Completed
Comparison of Clinical Effects of Meperidine and Sufentanil Added to 0.5% Hyperbaric Bupivacaine for Spinal Anesthesia in Patients Undergoing Cesarean Section [NCT04446715]60 participants (Anticipated)Interventional2020-10-01Recruiting
Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) [NCT02027311]Phase 463 participants (Actual)Interventional2013-04-30Completed
Comparison of the Role of Epidural Analgesia Versus Non-epidural Analgesia in Postnatal Depression and Persistent Pain Development: a Randomized Controlled Trial [NCT03167905]Phase 2/Phase 3881 participants (Actual)Interventional2017-06-15Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01229527 (2) [back to overview]Discharge Time, the Time to Reach a Modified Aldrete Score ≥18
NCT01229527 (2) [back to overview]Patient's Satisfaction
NCT01555671 (3) [back to overview]Duration of the Second Stage of Labour
NCT01555671 (3) [back to overview]The Duration of Active Phase of Labour
NCT01555671 (3) [back to overview]Total Duration of Labour
NCT01693185 (6) [back to overview]Participants Assumed to Feel Frequent Pain
NCT01693185 (6) [back to overview]Indigence of Patient's Recall
NCT01693185 (6) [back to overview]Endoscopist Satisfaction
NCT01693185 (6) [back to overview]Bispectra Lindex Score
NCT01693185 (6) [back to overview]Patient's Distress Score
NCT01693185 (6) [back to overview]The Recovery Time
NCT01709422 (2) [back to overview]Procedure Related Time
NCT01709422 (2) [back to overview]Cardiovascular Adverse Events.
NCT01741259 (25) [back to overview]Inadequate Analgesia
NCT01741259 (25) [back to overview]Dysphoria
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #9
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #8
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #1
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #2
NCT01741259 (25) [back to overview]Adverse Outcomes
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #4a
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #4b
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #4c
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #4d
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #5a
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #5b
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #5c
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #5d
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #6a
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #6b
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #6c
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #6d
NCT01741259 (25) [back to overview]Verbal Pain Score With Movement
NCT01741259 (25) [back to overview]Total Drug Dose
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #7
NCT01741259 (25) [back to overview]Pruritus
NCT01741259 (25) [back to overview]Nausea and Vomiting
NCT01741259 (25) [back to overview]American Pain Society Patient Outcome Questionnaire #3
NCT02027311 (2) [back to overview]Number of Intervention
NCT02027311 (2) [back to overview]Event of Hypoxia
NCT02486328 (6) [back to overview]Change in Cognitive Function
NCT02486328 (6) [back to overview]Peripheral Oxygen Saturation
NCT02486328 (6) [back to overview]Mean Arterial Pressure
NCT02486328 (6) [back to overview]Heart Rate
NCT02486328 (6) [back to overview]Change in Visual Analogue Scale Scores From the Baseline
NCT02486328 (6) [back to overview]Change in Cognitive Function
NCT02494180 (7) [back to overview]Patient's Satisfaction on Oocyte Retrieval
NCT02494180 (7) [back to overview]Pain Level During Oocyte Retrieval
NCT02494180 (7) [back to overview]Pain Level After Oocyte Retrieval
NCT02494180 (7) [back to overview]Patient's Satisfaction on Pain Relief
NCT02494180 (7) [back to overview]Ongoing Pregnancy Rate
NCT02494180 (7) [back to overview]Clinical Pregnancy Rate
NCT02494180 (7) [back to overview]Percentage of Participants With Side Effects by Type
NCT02625181 (4) [back to overview]Adherence to PONV Guidelines
NCT02625181 (4) [back to overview]PONV Incidence: Number of Participants With Postoperative Nausea and Vomiting
NCT02625181 (4) [back to overview]The Number of Prophylactic Interventions for PONV
NCT02625181 (4) [back to overview]Time to Discharge From the Postanesthesia Care Unit (PACU)
NCT02684942 (6) [back to overview]Fentanyl Dose
NCT02684942 (6) [back to overview]Meperidine Dose
NCT02684942 (6) [back to overview]Tumor Size
NCT02684942 (6) [back to overview]Pain Score
NCT02684942 (6) [back to overview]Quality of Life
NCT02684942 (6) [back to overview]Ovoids Size
NCT04068948 (1) [back to overview]Number of Participants With Successful Sedation

Discharge Time, the Time to Reach a Modified Aldrete Score ≥18

Ten key parameters (Activity, Respiration, Circulation, Consciousness, O2 Saturation, Dressing, Pain, Ambulation, Fasting-feeding, Urine Output)are included in the Modified Aldrete Score. The maximum and minimum score for each parameter is respectively 2 and 0. The maximum total score is 20 and patient can be discharged when the total score is ≥18. (NCT01229527)
Timeframe: > 0 minutes

Interventionminutes (Median)
Remifentanil RS10
Remifentanil RS20
Meperidine2

[back to top]

Patient's Satisfaction

The degree of satisfaction about the quality of sedation was measured with VAS (Visual Analog Scale) where 0 means no satisfaction and 100 means maximum satisfaction. (NCT01229527)
Timeframe: After the end of colonoscopy (when patients were completely awake) and 24 h after the procedure via telephone

Interventionunits on a scale (Mean)
Remifentanil RS195.87
Remifentanil RS293.50
Meperidine96.27

[back to top]

Duration of the Second Stage of Labour

The period of time until the birth of the baby, since the patient being followed for delivery (NCT01555671)
Timeframe: 24h

Interventionminutes (Mean)
Meperidine Administration Group24
Plasebo Group27

[back to top]

The Duration of Active Phase of Labour

The primary outcome is to evaluate whether meperidine is effective in shortening the duration of the active phase of labor (NCT01555671)
Timeframe: 24h

Interventionminutes (Mean)
Meperidine Administration Group249
Plasebo Group304

[back to top]

Total Duration of Labour

Total time of delivery of patients who gave birth including the second stage of delivery (NCT01555671)
Timeframe: 24h

Interventionminutes (Mean)
Meperidine Administration Group273
Plasebo Group331

[back to top]

Participants Assumed to Feel Frequent Pain

"patients sound Ah at feeling pain during colonosocpy: if a patients sounds Ah > 6 times, the patient was assumed to feel frequent pain." (NCT01693185)
Timeframe: during and after colonoscopy

Interventionparticipants (Number)
Remifentanil4
Midazolam and Meperidine7

[back to top]

Indigence of Patient's Recall

The numbers of patients who recalled instructions and explanations given during colonoscopy (NCT01693185)
Timeframe: after colonoscopy

Interventionparticipants (Number)
Remifentanil27
Midazolam and Meperidine13

[back to top]

Endoscopist Satisfaction

endoscopist's satisfaction after colonoscopy in visual analogue scale 100 mm (NCT01693185)
Timeframe: 5 min after the colonoscopy

Interventionunits on a scale (Median)
Remifentanil5
Midazolam and Meperidine20

[back to top]

Bispectra Lindex Score

Bispectral index (BIS) score 0-100 maximal sedation=0, maximal sedation=100 (NCT01693185)
Timeframe: every 5 min during and after colonoscopy

Interventionunits on a scale (Median)
Remifentanil92
Midazolam and Meperidine84

[back to top]

Patient's Distress Score

patients' distress in visual analogue scale 100 mm minimal distress=0, maximal distress=100 (NCT01693185)
Timeframe: 5 min after the end of colonoscopy

Interventionunits on a scale (Median)
Remifentanil37
Midazolam and Meperidine30

[back to top]

The Recovery Time

"Time from completing the colonoscopy to achieving Aldrete score 10 in the recovery unit~Aldrete score~Respiration: Able to take deep breath and cough = 2, Dyspnea/shallow breathing = 1, Apnea = 0~O2 saturation: Maintains > 92% on room air =2, Needs O2 inhalation to maintain O2 saturation > 90% =1 , O2 saturation < 90% even with supplemental oxygen =0~Consciousness: Fully awake= 2, Arousable on calling = 1, Not responding = 0~Circulation: BP +/- 20 mm Hg preop =2, BP +/- 20-50 mm Hg preop =1, BP +/- 50 mm Hg preop =0~Activity: Able to move 4 extremities = 2, Able to move 2 extremities = 1, Able to move 0 extremities = 0~To estimate the required sample size, we conducted a pilot study to measure the recovery of 10 patients in each of groups-MM and -R before the present study. The means and standard deviations were 22.5 ± 9.5 and 7.5 ± 9.2 min respectively. We wished to be able to distinguish a difference of 7.5 min, thus half of the observed difference." (NCT01693185)
Timeframe: every 5 minutes after completing colonoscopy up to 30 min

Interventionminute (Median)
Remifentanil0
Midazolam and Meperidine30

[back to top] [back to top]

Cardiovascular Adverse Events.

(1) desaturation(oxygen saturation < 90 % at least 10 second ) (2) hypotension ( systolic blood pressure < 90 mmHg or dropped more than 25 % of baseline ) (3)bradycardia (heart rate < 50 beats/min) and (4) apnea ( cessation of respiratory activity for over 10 seconds ). When patients developed oxygen saturation < 90 %, then nasal oxygen was administered, If patients not able to recover from oxygen therapy and tactile stimulations thus the procedure was terminated. The procedure was terminated if patients developed serious adverse event as heart rate below 5 beats/min and or apnea. (NCT01709422)
Timeframe: participants will be followed for the duration of procedure, an expected average of 2.0 hours

,
InterventionParticipants (Number)
Participants with desatuartionParticipants with hypotensionParticipants with bradycardia
Midazolam and Meperidine40140
Propofol,Midazolam and Meperidine26121

[back to top]

Inadequate Analgesia

Patients routinely get scheduled ibuprofen as an adjunct to the epidural infusion. The record will be reviewed to see if ketorolac is substituted for ibuprofen or other pain medications such as acetaminophen either alone or in combination with oxycodone or other narcotic pain relievers are administered. The record will also be reviewed if an epidural is discontinued earlier than the morning of the second post-operative day to find out if inadequate analgesia was the cause. (NCT01741259)
Timeframe: 36-48 hours post-op (until the epidural is stopped)

Interventionparticipants (Number)
Meperidine PCEA7
Meperidine PCEA With Basal3

[back to top]

Dysphoria

The incidence of dysphoria will be captured when a nurse calls the anesthesia team to alert them. This information is tracked on the physician rounding sheet. The record will also be reviewed if an epidural is discontinued earlier than the morning of the second post-operative day to find out if dysphoria was the cause. (NCT01741259)
Timeframe: 36-48 hours post-op (until epidural is stopped)

Interventionparticipants (Number)
Meperidine PCEA0
Meperidine PCEA With Basal0

[back to top]

American Pain Society Patient Outcome Questionnaire #9

On a 0-10 scale, how satisfied are you with the results of your pain treatment with 0 being extremely dissatisfied and 10 being extremely satisfied. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA8.76
Meperidine PCEA With Basal9.41

[back to top]

American Pain Society Patient Outcome Questionnaire #8

On a 0-10 scale, were you allowed to participate in decisions about your pain treatment as much as you wanted to with 0 being not at all and 10 being entirely. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA8.996
Meperidine PCEA With Basal9.258

[back to top]

American Pain Society Patient Outcome Questionnaire #1

Please indicate on 0-10 scale the least pain you had in first 24 hours. 0 represents no pain and 10 represents the worst pain possible. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA1.89
Meperidine PCEA With Basal1.45

[back to top]

American Pain Society Patient Outcome Questionnaire #2

On 0-10 scale, indicate the worst pain you had in first 24 hours. 0 represents no pain and 10 represents the worst pain possible. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA5.79
Meperidine PCEA With Basal5.10

[back to top]

Adverse Outcomes

Adverse outcomes such as seizures or respiratory depression will be reported to anesthesia personnel by nursing if they occur. Patients are monitored for respiratory rate and sedation every 1 hour for 24 hours, then every 2 hours for 24 hours. Pulse, blood pressure, and neurocirculatory checks are performed every 2 hours for 24 hours and then every 4 hours per our nursing protocol. (NCT01741259)
Timeframe: 36-48 hours post-op (until the epidural is stopped)

Interventionparticipants (Number)
Meperidine PCEA0
Meperidine PCEA With Basal0

[back to top]

American Pain Society Patient Outcome Questionnaire #4a

How much, on 0-10 scale, did pain interfere with doing activities in bed (turning, sitting up, repositioning) where 0 is does not interfere and 10 is completely interferes. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA4.04
Meperidine PCEA With Basal3.13

[back to top]

American Pain Society Patient Outcome Questionnaire #4b

How much, on a 0-10 scale, did pain interfere with doing activities out of bed (walking, sitting in chair, standing at sink) where 0 is does not interfere and 10 is completely interferes. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA4.02
Meperidine PCEA With Basal3.71

[back to top]

American Pain Society Patient Outcome Questionnaire #4c

How much, on a 0-10 scale, did pain interfere with falling asleep where 0 is does not interfere and 10 is completely interferes. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA2.016
Meperidine PCEA With Basal1.487

[back to top]

American Pain Society Patient Outcome Questionnaire #4d

How much, on a scale of 0-10, did pain interfere with staying asleep where 0 is does not interfere and 10 is completely interferes. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA2.04
Meperidine PCEA With Basal1.68

[back to top]

American Pain Society Patient Outcome Questionnaire #5a

On a scale of 0-10, how much did the pain cause you to feel anxious where 0 is not at all anxious and 10 is extremely anxious. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA1.311
Meperidine PCEA With Basal1.504

[back to top]

American Pain Society Patient Outcome Questionnaire #5b

On a scale of 0-10, how much did pain cause you to feel depressed where 0 is not al all and 10 is extremely. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA.47
Meperidine PCEA With Basal.34

[back to top]

American Pain Society Patient Outcome Questionnaire #5c

How much, on a scale of 0-10, did the pain cause you to feel frightened where 0 is not at all and 10 is extremely. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA.85
Meperidine PCEA With Basal.79

[back to top]

American Pain Society Patient Outcome Questionnaire #5d

How much, on a scale of 0-10, did the pain cause you to feel helpless where 0 is not at all and 10 is extremely. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA1.42
Meperidine PCEA With Basal1.49

[back to top]

American Pain Society Patient Outcome Questionnaire #6a

On a scale of 0-10, what was the severity of your nausea where 0 is none and 10 is severe. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA.49
Meperidine PCEA With Basal.69

[back to top]

American Pain Society Patient Outcome Questionnaire #6b

On a 0-10 scale, how severe was your drowsiness where 0 is none and 10 is severe. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA2.26
Meperidine PCEA With Basal2.91

[back to top]

American Pain Society Patient Outcome Questionnaire #6c

On a 0-10 scale, how severe was your itching where 0 is none and 10 is severe. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA2.661
Meperidine PCEA With Basal2.419

[back to top]

American Pain Society Patient Outcome Questionnaire #6d

On a 0-10 scale, how severe was your dizziness where 0 is not at all and 10 is extremely. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionunits on a scale (Mean)
Meperidine PCEA.84
Meperidine PCEA With Basal1.13

[back to top]

Verbal Pain Score With Movement

Verbal Pain Score on a 0-10 scale is recorded by the nurse at 0, 4, 8, 12, 16, 20, 24, 28, 32, 36,40, 44, and 48 hours after transfer to the post-partum floor. On this scale, 0 represents no pain at all and 10 represents the worst pain imaginable. Because we were relying on nurses to capture this data in the course of normal patient care, scores within 1 hour before or after the goal time were accepted. For each patient, the average of all pain scores was taken and this was considered to be the average pain score while the epidural meperidine was being given. (NCT01741259)
Timeframe: 36-48 hours post-op (until epidural is stopped)

Interventionunits on a scale (Mean)
Meperidine PCEA1.92
Meperidine PCEA With Basal1.50

[back to top]

Total Drug Dose

Pharmacy will generate a report of the drug total from the pump on return to pharmacy. (NCT01741259)
Timeframe: 48 hours post-op or when the epidural is stopped

Interventionmilligrams of drug per hour (Mean)
Meperidine PCEA5.42
Meperidine PCEA With Basal8.49

[back to top]

American Pain Society Patient Outcome Questionnaire #7

Select the percentage (from 0%-100%) of pain relief you received from all medical and non-medical treatments in the first 24 hours. 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionpercentage of pain relieved (Mean)
Meperidine PCEA77.05
Meperidine PCEA With Basal81.82

[back to top]

Pruritus

The incidence of pruritus will be estimated by the administration of diphenhydramine or nalbuphine during the study period as recorded in the patient record. (NCT01741259)
Timeframe: 36-48 hours post-op (until the epidural is stopped)

Interventionparticipants (Number)
Meperidine PCEA20
Meperidine PCEA With Basal10

[back to top]

Nausea and Vomiting

The incidence of nausea and vomiting will be estimated by the administration of ondansetron during the study period as recorded in the patient record. (NCT01741259)
Timeframe: 36-48 hours post-op (until epidural is stopped)

Interventionparticipants (Number)
Meperidine PCEA1
Meperidine PCEA With Basal3

[back to top]

American Pain Society Patient Outcome Questionnaire #3

How often were you in severe pain in the first 24 hours (percentage 0-100%). 122 patients in the Meperidine PCEA no basal group completed their questionnaires while 118 in the Meperidine PCEA with basal group completed a questionnaire. Some patients did not answer all the questions on the questionnaire, if a question was left blank, it was not analyzed for that patient but the rest of the questionnaire was included. (NCT01741259)
Timeframe: Survey day epidural stopped

Interventionpercentage of time (Mean)
Meperidine PCEA14.47
Meperidine PCEA With Basal11.78

[back to top]

Number of Intervention

The frequency of intervention which was defined as any restraint of the patient's head, arms, or legs if they became agitated, or if patient movement was not controlled with verbal instruction from the endoscopist during the whole intraoperative phases. (NCT02027311)
Timeframe: Throughout the whole ERCP procedure

InterventionNumber of intervention (Mean)
Etomidate1.9
Midazolam7.5

[back to top]

Event of Hypoxia

Hypoxia defined as peripheral blood oxygen saturation measured by pulse oxymeter < 90% (NCT02027311)
Timeframe: Every 5min in Preoperative, intraoperative phase and 15 min in Recovery phase

InterventionHypoxia events (Number)
Midazolam19
Etomidate27

[back to top]

Change in Cognitive Function

As measured by Digit Symbol Substitution Test. Scale range 0-9. No cut-off value. Higher results represent better outcomes (NCT02486328)
Timeframe: Baseline and 5, 15, 30 minutes after the procedure

,
Interventionunits on a scale (Mean)
5th minute15th minute30th minute
Group MM1.62.12.4
Group RP22.83.5

[back to top]

Peripheral Oxygen Saturation

peripheral oxygen saturation as measured by pulse oximeter. Units are percentages, Scale range 0-100. (NCT02486328)
Timeframe: Baseline and 1,2,3,5,10,15 and 20 minutes

,
InterventionPercent of oxygenated hemoglobin (Mean)
baseline1 minute in procedure2 minute in procedure3 minute in procedure5 minute in procedure10 minute in procedure15 minute in procedure20 minute in procedure
Group MM97.297.297.597.697.497.297.297.4
Group RP98.69898.598.497.198.198.398.2

[back to top]

Mean Arterial Pressure

mean arterial blood pressure as measured in mmHg (NCT02486328)
Timeframe: Baseline and 1,2,3,5,10,15 and 20 minutes

,
InterventionmmHg (Mean)
baseline1 minute in procedure2 minute in procedure3 minute in procedure5 minute in procedure10 minute in procedure15 minute in procedure20 minute in procedure
Group MM105.7103104.5105.8101.5103.8102.499.3
Group RP113.110492.989.387.110091.694.3

[back to top]

Heart Rate

Heart rate as measured in beats per minute (NCT02486328)
Timeframe: Baseline and 1,2,3,5,10,15 and 20 minutes

,
Interventionbeats per minute (Mean)
baseline1 minute in procedure2 minute in procedure3 minute in procedure5 minute in procedure10 minute in procedure15 minute in procedure20 minute in procedure
Group MM90.289.68887.687.785.385.485
Group RP82.681.37669.970.37071.673.1

[back to top]

Change in Visual Analogue Scale Scores From the Baseline

Pain as measured by Visual Analogue Scale. Range 1-10. No cut-off value, Higher results represent worse outcomes (NCT02486328)
Timeframe: Baseline and 5, 15, 30 minutes after the procedure

,
Interventionunits on a scale (Mean)
5 minutes after the procedure15 minutes after the procedure30 minutes after the procedure
Group MM0.90.50.1
Group RP0.40.40.1

[back to top]

Change in Cognitive Function

As measured by Trieger Dot Test. The test does not have an upper limit; the time taken to complete the test is added to the number of dots missed by the patient and a result is obtained. The lowest score possible is 0. Higher values represent worse outcomes. (NCT02486328)
Timeframe: Baseline and 5, 15, 30 minutes after the procedure

,
Interventionunits on a scale (Mean)
5th minute15th minute30th minute
Group MM47.544.742
Group RP40.437.835.4

[back to top]

Patient's Satisfaction on Oocyte Retrieval

satisfaction will be scored from 0-3 (0=excellent, 1=satisfactory, 2=fair, 3=unsatisfactory) (NCT02494180)
Timeframe: will be assessed within 4 hours of oocyte retrieval

,
Interventionpercentage of participants (Number)
excellentsatisfactoryfairunsatisfactory
A: Intravenous Fentanyl, Midazolam47.738.811.84.7
B: Intravenous Pethidine, Diazepam15.355.322.47.1

[back to top]

Pain Level During Oocyte Retrieval

The pain level will be scored using visual analogue scale 0-10, 0 = no pain, 10 =most painful (NCT02494180)
Timeframe: will be assessed within 4 hours of oocyte retrieval

,
Interventionscore on a scale (Median)
vaginal painabdominal pain
A: Intravenous Fentanyl, Midazolam02.5
B: Intravenous Pethidine, Diazepam45

[back to top]

Pain Level After Oocyte Retrieval

The pain level will be scored using visual analogue scale 0-10, 0 = no pain, 10 =most painful (NCT02494180)
Timeframe: will be assessed within 4 hours of oocyte retrieval

,
Interventionscore on a scale (Median)
vaginal painabdominal pain
A: Intravenous Fentanyl, Midazolam02.3
B: Intravenous Pethidine, Diazepam02

[back to top]

Patient's Satisfaction on Pain Relief

satisfaction on pain relief will be scored at 0-10 (10 being most satisfied) (NCT02494180)
Timeframe: within 4 hours after retrieval

Interventionscore on a scale (Median)
A: Intravenous Fentanyl, Midazolam8
B: Intravenous Pethidine, Diazepam7

[back to top]

Ongoing Pregnancy Rate

positive fetal heart pulsation seen in ultrasound at eight weeks of gestation (NCT02494180)
Timeframe: will be assessed within ten weeks of oocyte retrieval

Interventionpercentage of participants (Number)
A: Intravenous Fentanyl, Midazolam12.9
B: Intravenous Pethidine, Diazepam21.2

[back to top]

Clinical Pregnancy Rate

presence of intrauterine sac in ultrasound after a positive pregnancy test (NCT02494180)
Timeframe: will be assessed within ten weeks of oocyte retrieval

Interventionpercentage of participants (Number)
A: Intravenous Fentanyl, Midazolam14.1
B: Intravenous Pethidine, Diazepam23.5

[back to top]

Percentage of Participants With Side Effects by Type

side effects will be scored by yes or no (NCT02494180)
Timeframe: will be assessed within 4 hours of oocyte retrieval

,
Interventionpercentage of participants (Number)
nauseavomitingdizzinessdrowsinessshortness of breath
A: Intravenous Fentanyl, Midazolam2.4016.58.20
B: Intravenous Pethidine, Diazepam7.11.24.73.51.2

[back to top]

Adherence to PONV Guidelines

PONV guideline adherence: percentage of patients who received the exact number of prophylactic interventions for PONV that were recommended by the decision support. (NCT02625181)
Timeframe: A specific time frame on the day of surgery: the start of admission at the holding room to the end of the anesthetic case

InterventionParticipants (Count of Participants)
Baseline Measurement666
CDS Email Recommendations5260
CDS Email + Real TIme Recommenations5863

[back to top]

PONV Incidence: Number of Participants With Postoperative Nausea and Vomiting

The occurrence of PONV, as defined by the administration of antiemetics in the PACU between admission to PACU and discharge from PACU. (NCT02625181)
Timeframe: PACU recovery period

InterventionParticipants (Count of Participants)
Baseline Measurement139
CDS Email Recommendations1323
CDS Email + Real TIme Recommenations1343

[back to top]

The Number of Prophylactic Interventions for PONV

the absolute number of prophylactic interventions applied between the admission of the patient in the holding room until admission to the PACU. (NCT02625181)
Timeframe: A specific time frame on the day of surgery: from the start of admission at the holding room to the end of the anesthetic case

Interventionprophylactic antiemetics administered (Mean)
Baseline Measurement2.196
CDS Email Recommendations2.176
CDS Email + Real TIme Recommenations2.129

[back to top]

Time to Discharge From the Postanesthesia Care Unit (PACU)

This is the number of minutes from admission to the PACU until discharge, assessed up to 2 days (NCT02625181)
Timeframe: A specific time frame on the day of surgery: from the start of admission to the PACU to discharge from the PACU

Interventionminutes (Mean)
Baseline Measurement266
CDS Email Recommendations264
CDS Email + Real TIme Recommenations266

[back to top]

Fentanyl Dose

Sum of fentanyl dose when finish each fraction of brachytherapy (NCT02684942)
Timeframe: after complete treatment.

Interventionug. (Mean)
Fentanyl100.18

[back to top]

Meperidine Dose

Sum of meperidine dose when finish each fraction of brachytherapy (NCT02684942)
Timeframe: after complete treatment.

Interventionmg. (Mean)
Meperidine50.13

[back to top]

Tumor Size

Size of tumor at cervix measured by the doctor before insert applicator. (NCT02684942)
Timeframe: Before insert applicator in each fraction of brachytherapy.

InterventionCM. (Mean)
Meperidine2.23
Fentanyl2.21

[back to top]

Pain Score

Perceived pain score according to standard 10-cm visual analog scales (VAS) was assessed before injection of medicine for every 15 minutes up to 120 minutes.The minimum and maximum scores were 0, 10. Score 0 means no pain, 1-3 mild pain, 4-6 moderate pain, 7-9 severe pain and 10 worst pain. (NCT02684942)
Timeframe: From date of the first fraction until date of the last fraction of brachytherapy, once a week for four weeks

,
Interventionunits on a scale (Mean)
baseline0 minute15 minute30 minute45 minute60 minute75 minute90 minute105 minute120 minute
Fentanyl0.140.400.651.241.700.810.530.130.130.13
Meperidine0.040.490.591.051.330.610.490.240.240.24

[back to top]

Quality of Life

Perceived Quality of life (EQ-5D) was assessed before the first brachytherpy and immediately after completion of each of the 4 brachytherapy fractions. The EQ-5D have 5 dimensions: mobility, self-care, usual activities, topics each content 3 responses: no problems, some problems, extreme problems. (NCT02684942)
Timeframe: From date of the first fraction of brachytherapy until date of the last fraction of brachytherapy,once a week for 4 weeks

,
Interventionparticipants (Number)
No problems in mobilitySome problems in mobilitySevere problems in mobilityNo problem in self-careSome problem in self-careSevere problem in self-careNo problem in usual activitiesSome problem in usual activitiesSevere problem in usual activitiesNo problem in pain/discomfortSome problem in pain/discomfortSevere problem in pain/discomfortNo problem in anxiety/depressionSome problem in anxiety/depressionSevere problem in anxiety/depression
Fentanyl581816962532132353142332
Meperidine6216168110552222749346321

[back to top]

Ovoids Size

Size of ovoids that a pair part of brachytherapy applicator insert in vagina trough cervix. (NCT02684942)
Timeframe: after complete applicator insertion.

InterventionCentimeter (Median)
Meperidine2
Fentanyl2

[back to top]

Number of Participants With Successful Sedation

Children's behavior during sedation is rated on the Houpt Behavior Rating Scale. A successful sedation is rated as Excellent, Very Good, or Good. A failed sedation is rated as Fair, Poor, or Aborted. (NCT04068948)
Timeframe: At completion of procedure

InterventionParticipants (Count of Participants)
Midazolam, Hydroxyzine, Meperidine11
Midazolam, Hydroxyzine9

[back to top]